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 Parvovirus B19 (B19V) is a small, non-enveloped virus that contains a single-stranded DNA 
(ssDNA) genome of 5.6 kb in size. B19V is pathogenic to humans and causes bone marrow 
failure diseases and various other inflammatory disorders. B19V infection exhibits high tropism 
for human erythroid progenitor cells (EPCs) in the bone marrow and fetal liver. The exclusive 
restriction of B19V replication to erythroid lineage cells is partly due to the expression of 
receptor and co-receptor(s) on the cell surface of human EPCs and partly depends on the 
intracellular factors essential for virus replication. On this rationale, we tried to investigate the 
essential host factors for efficient virus replication. Our results demonstrated that signal 
transducer and activator of transcription 5 (STAT5) and RNA-binding motif protein-38 
(RBM38) are two of these important host factors that ensure virus DNA replication and pre-
mRNA processing, respectively, during B19V infection. The stages of erythropoiesis during 
which STAT5 is activated and RBM38 is expressed, are highly susceptible to B19V infection, 
thus suggesting that these two factors are among the key determinants of the B19V restriction to 
human EPCs. 
             B19V requires erythropoietin (EPO) signaling and hypoxia for its efficient replication. 
EPO to EPO receptor signaling activates JAK2-STAT5 pathway that phosphorylates STAT5. In 
our first study, we show that phosphorylated STAT5 is critical for B19V replication. Upon in-
silico analysis, we identified a consensus STAT5 binding element adjacent to the NS1-binding 
elements within the minimal origin of viral DNA replication (Ori) in the B19V genome.  The 
phosphorylated STAT5 specifically interacts with viral Ori both in vivo and in vitro, and is 
actively recruited within the viral DNA replication centers.  Furthermore, our study shows a 
novel interaction between STAT5 and the minichromosome maintenance (MCM) complex. Our 
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proposed model suggests that STAT5 directly facilitates viral DNA replication by recruiting 
MCM complex into viral DNA replication centers. Interestingly, we found that pimozide, a 
STAT5 phosphorylation inhibitor and an FDA-approved drug, inhibits B19V replication in ex 
vivo expanded EPCs, suggesting that pimozide could be a promising antiviral drug for the 
treatment of B19V-related pathologies.  
            B19V expresses a single precursor mRNA (pre-mRNA), which undergoes alternative 
splicing and alternate polyadenylation to generate 12 viral mRNA transcripts. Splicing at the 
second 5’ donor site (D2) of the B19V pre-mRNA is essential for the expression of VP1, VP2 
and 11-kDa. We have previously identified that a cis-acting intronic splicing enhancer 2 (ISE2) 
that lies immediately after the D2 site facilitates recognition of the D2 donor for its efficient 
splicing. In our second study, we described that ISE2 harbors a consensus RBM38 binding 
sequence–5’-UGUGUG-3’. RBM38 is expressed during the middle stage of erythropoiesis. We 
first confirmed that the RBM38 binds specifically with the ISE2 element in vitro. Knockdown of 
RBM38 significantly decreases the level of the spliced mRNA at D2 that encodes 11-kDa protein 
and, thereafter, the expression of the 11-kDa protein. Importantly, we found that the 11-kDa 
protein enhances viral DNA replication and virion release. Accordingly, knockdown of RBM38 
decreases virus replication via downregulating 11-kDa expression. Taken together, these results 
suggest that the 11-kDa protein facilitates B19V DNA replication, and that RBM38 is an 
essential host factor for the splicing of B19V pre-mRNA from D2 to A2-2 sites and for the 
expression of the 11-kDa protein.  In conclusion, we identified two host factors, STAT5 and 
RBM38, which play important roles in B19V replication. We provide a mechanistic overview of 
how STAT5 facilitates virus DNA replication and RBM38 promotes the splicing of B19V pre-
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Human parvovirus B19 (B19V) infects erythroid progenitor cells in the bone marrow and fetal 
liver. The specific tropism of B19V for erythroid precursor cells partially relies on the 
intracellular factors in erythroid-lineage cells. In human CD36+ erythroid progenitor cells 
(EPCs), erythropoietin signaling is not only required for the cell differentiation and development, 
but is also indispensable for B19V replication. Specifically, Signal Transducer and Activator of 
Transcription- 5 (STAT5) activation is critical for viral DNA replication. B19V replication-
induced DNA damage response (DDR) also plays an important role in the virus replication. 
B19V multiplies efficiently under hypoxic conditions. B19V induces cell cycle arrest, initially at 
late S-phase, during which B19V fully exploits S-phase factors to replicate the viral genomes. 
Later B19V causes G2 arrest that leads to cell death of EPCs. B19V encodes a single precursor 
mRNA, which harbors two splice donor sites and four acceptor sites. The use of extensive 
alternate splicing and alternative polyadenylation generates at least 12 different species of 
mRNA transcripts. Both the processes of alternate splicing and alternative polyadenylation are 
tightly regulated through cis-acting elements and trans-acting factors flanking the splice donor 
or acceptor sites. In this introductory chapter, we focus on recent advances in the molecular 





Parvovirus B19 (B19V) is a small, non-enveloped virus that has a diameter of 
approximately 23-26 nm and contains a linear single-stranded DNA genome of 5.6 kb, flanked 
by two identical terminal hairpin structures (Fig. 1-1A) (1). B19V belongs to Erythroparvovirus 
of the Parvoviridae family. The name B19 was coined after the sample number containing the 
virus; panel B and no.19, during the screening of hepatitis B virus (2). B19V infection causes 
several diseases in humans, including like fifth disease in children, transient aplastic crisis, non-
immune hydrops fetalis in pregnant women, persistent anemia in immunocompromised patients, 
arthropathy, cardiomyopathy and inflammation of various other tissues (1). 
            In this chapter, we focus on recent advances in B19V tropism, viral DNA replication and 
viral transcription. Importantly, we will focus on four key factors involved in B19V replication 
that are: a) erythropoietin (EPO) signaling; b) hypoxia; c) DNA damage response (DDR); and d) 
late S-phase arrest. We also summarize the new advancements in B19V pre-mRNA processing 
and its regulation. We also discuss host factors STAT5 and RBM38 (RNA-Binding Motif 
protein- 38), which regulate virus replication and mRNA processing, respectively. Lastly, we 
discuss the underlying mechanism of NS1 induced cell cycle arrest, B19V pathogenesis, and the 









Viral entry and determinants of viral tropism 
            Productive infection of B19V is restricted to human erythroid progenitor cells, 
particularly, during the stages of burst forming unit-erythroid (BFU- E) to colony forming unit- 
erythroid (CFU-E) (3,4). B19V infects ex vivo expanded EPCs from human bone marrow (3-5), 
peripheral and umbilical blood (6-9) and the fetal liver (10,11). In addition to expanded primary 
EPCs, various other cell lines have been used for B19V infection, including MB-02, UT7/Epo 
and UT7/Epo-S1 (megakaryoblastoid cell lines) (12-14) and JK-1, KU812-Ep6 (erythroid 
leukemia cell lines) (15,16). For efficient B19V replication, erythropoietin and hypoxia play a 
critical role under in vitro conditions (17,18). B19V also infects endothelial cells of various 
tissues, but the infection is largely non-productive (19). In addition, U937 cells, circulating 
angiogenic cells (CACs) and CD34+ endothelial progenitor cells from bone marrow have also 
been reported to be susceptible to B19V infection (20-22). All these cells either express viral 
receptor/co-receptors or use an antibody dependent route via c1q receptor for viral entry (23). 
            The primary receptor for B19V is globoside or P antigen (Fig. 1-2) (24). However, all P 
antigen expressing cells are not permissive to B19V (25). Various other co-receptors like Ku80 
(26), integrin α5β1 (27) and antibody-mediated B19V entry routes (23) are presumed to be 
involved in B19V entry. Importantly, the B19V capsid binds its primary receptor, P antigen and 
undergoes a conformational change, exposing VP1u, a unique (273 aa) N-terminus of the VP1 
capsid protein (Fig. 1-2) (28-30). Since Ku80 and α5β1 integrin haven’t been shown to interact 
with VP1u, it has been hypothesized that VP1u interacts with some unknown co-receptor for 
subsequent internalization. Further, the N-terminal 100 amino acids of VP1u are required for 
internalization, which implies that the PLA2 (phospholipase A2) activity of VP1u is not essential 
for viral entry (31). Interestingly, the VP1u region (without capsid) is efficiently internalized by 
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B19V-permissive cells (32,33), which suggests that primary interaction of B19V with P antigen 
is required only for externalization of VP1u. Mature RBCs also express P antigen and hence 
show primary attachment to B19V, as the virus is not internalized (29). It is presumed that this 
primary interaction may be responsible for systemic dissemination of the virus. Similar to other 
parvoviruses, B19V uses the endocytic pathway but escapes lysosomal degradation to enter the 




















Gene expression, splicing, and its regulation 
            Upon entry of the virus into the nucleus, the B19V ssDNA genome is converted to 
double-stranded replicative form (dsRF), which acts a template for both DNA replication and 
transcription (Fig. 1-2) (36). The dsRF viral DNA has a unique but single promoter at map unit 6 
(P6) that expresses a single precursor mRNA (pre-mRNA) (Fig. 1-1B) (37,38).  The P6 promoter 
has an upstream enhancer region and NS1 elements that bind transcription factors (e.g. CREBP, 
GATA, Oct1 etc.) and NS1 protein, respectively, for promoter transactivation (39-42). B19V 
pre-mRNA undergoes alternative splicing and polyadenylation to express at least 12 mature 
mRNA transcripts that encode two structural (VP1 & VP2) and three non-structural (NS1, 7.5-
kDa & 11-kDa) proteins (43-45). The pre-mRNA contains two splice donor sites (D1 & D2) and 
four acceptor sites (A1-1, A1-2, A2-1 & A2-2) (Fig. 1-1B) (1). In addition, it harbors two 
proximal [(pA)p]1/2 and a distal [p(pA)d] polyadenylation sites (Fig. 1-1B) (1). Unspliced 
mRNA transcripts (R1&R1’) that polyadenylate at (pA)p encode the NS1 protein while those 
spliced at A1-1 (R2 & R2’) and use (pA)p sites encode the 7.5-kDa protein (Fig. 1-1B). The 
mRNA transcripts polyadenylated at (pA)d and where 1st  intron (R4 & R5),  1st  and 2nd (R6 & 
R7), or 1st , 2nd and 3rd introns (R8 & R9) are spliced out encode the VP1, VP2 and 11-kDa 
proteins, respectively (Fig. 1-1B)  (44,46,47). Whether other mRNAs (R3 & R3’) encode a 
protein or play any role during virus infection is unknown.  
            While the B19V mRNAs are splice products from a single pre-mRNA, the expression 
levels of the different encoded proteins vary considerably.  Therefore, the virus must employ 
different strategies to regulate the level of gene expression. In absence of viral DNA replication, 
most mRNA transcripts polyadenylate at (pA)p leading to the expression of NS1 and 7.5-kDa 
proteins in both B19V-permisssive or non-permissive cells (Fig. 1B)  (48). Viral DNA 
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replication facilitates the read through of (pA)p and overcomes the blockade to express mRNAs 
that polyadenylate at (pA)d encoding for the VP1, VP2 and 11-kDa proteins (49). Thus, the early 
and late phases of virus infection are dominated by NS1-encoding and VP/11-kDa-encoding 
mRNAs, respectively (50). An alternative model for virus infection was also proposed 
suggesting that B19V genome be considered as single, two state replicative and transcription 
unit, where the increase in viral RNA correlates with viral DNA levels (51). Next, the central 
exon or exon 2 (spanning A1-1/2 to D2) harbors serine arginine (SR) protein binding GAA 
motifs, and the GAA motif between A1-1 and A1-2, constitutes exon splicing enhancer 1 
(ESE1), which defines exon-2 and facilitates splicing at A1-1. The 5’ end of exon 2 promotes 
splicing at A1-2 and serves as exon splicing enhancer 2 (ESE2) (52). Splicing at second donor 
site (D2) is critical for the expression of capsid and 11-kDa encoding mRNAs, and also competes 
with polyadenylation at (pA)p (53). Binding of U1 snRNA to D2 splice donor site inhibits 
polyadenylation at (pA)p (52). D2 is a weak splice donor site and requires two cis-acting 
elements: exon splicing enhancer 3 (ESE3) and intron splicing enhancer 2 (ISE2) for its efficient 
splicing (52). Hence, the interplay of cis-acting elements and trans-acting factors determine the 
splicing efficiency of different splice sites to regulate the expression of different mRNA species. 
While looking for the trans-acting factors that bind ISE2, our results in chapter 3 demonstrate 
that RNA binding protein-RBM38, expressed in the middle stages of erythropoiesis, promotes 
the expression of 11-kDa protein. Specifically, RBM38 binds ISE2 and promotes splicing of the 
third intron (D2 to A2-2), that results in the production of 11-kDa encoding mRNAs. Therefore, 
RBM38 is one of the essential trans-acting factors that regulates the expression of 11-kDa 




Viral Proteins and their functions 
B19V expresses two structural proteins (VP1 & VP2) and three non-structural proteins 
(NS1, 11-kDa & 7.5-kDa). 
Non-structural proteins. 
Non-structural protein 1 (NS1). NS1 is 671 amino acid long protein that has a MW of ~ 
78 kDa by SDS-PAGE.  NS1 contains two nuclear localization signals; KKPR (177-179) and 
KKCGKK (316-321) (Fig. 1-3) and is found predominantly in the nucleus of infected cells 
(43,55-57). NS1 contains a DNA binding and endonuclease domain at N-terminus (58), ATPase 
and NTP-binding domains in the central region (59) and a transactivation domain at its C-
terminus (60) (Fig. 1-3). NS1 is critical for virus DNA replication (61), and binds NSBEs (NS1 
binding elements) of the minimum origin of replication of B19V dsRF DNA (Fig. 1-4) (58). 
Upon NS1 binding to NSBEs, it presumably opens up the dsRF DNA and nicks the ssDNA 
substrate at trs (terminal resolution site) (Fig. 1-2) (62). With the assistance of Sp1/Sp3, NS1 
binds P6 promoter for its transactivation (63,64). NS1 induces apoptosis via NTP-binding motif 
(328-335 amino acid) (59,65,66), a DNA damage response  (60,67) and cell cycle arrest (57,68-
70). The putative transactivation domain TAD2 of NS1 is critical for cell cycle arrest and the 
transactivation of host genes. NS1 is thought to be a global transactivator as the expression of 
NS1 protein in UT7/Epo-S1 affected around 1,770 genes, by upregulating 1,064 genes and 
downregulating 706 genes (70). In short, NS1 is a multifunctional protein and plays various roles 
during B19V infection (Fig. 1-5). 
11-kDa protein.  The 11-kDa protein is expressed at high levels during B19V infection 
and localizes more in cytoplasm than nucleus of infected cells.   The abundance of the 11-kDa 
protein in cytoplasm of infected cells is at least 100 times greater than NS1 protein (47,71).  The 
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11-kDa protein is potent inducer of apoptosis during B19V infection and involves caspase-10 
(Fig. 1-2) (71). In chapter 3, our results demonstrate that the 11-kDa protein enhances viral DNA 
replication (~10 fold), and thus determines virion production (54).  Finally, the 11-kDa protein 
has also been implicated in VP2 production and its distribution (61). 
7.5-kDa protein. The function(s) of 7.5-kDa are still unknown. 
Structural proteins. 
Capsid proteins (VP1 & VP2). VP1 is a minor capsid protein, 781 amino acids long (~ 
84 kDa) (56). VP1 shares the same C-terminus with VP2, with extra 273 amino acids, called as 
VP1-unique (VP1u) (43,56). VP2 is a major capsid protein, 554 amino acid long (~ 58 kDa) 
(56). VP1 expression is low (72) and with VP2 assemble into viral capsid (VP1:VP2= 1:20) (Fig. 
1-2)  (56). VP2 has nuclear localization signal at C-terminus, therefore both proteins are found in 
the nucleus of infected cells(73). The capsid first interacts with P antigen (Fig. 1-2) (24) and 
thereafter first 100 amino acids of VP1u help in internalization of the virus particles (31). VP1u 
region from 128 to 160 amino acids exhibits phospholipase A2 activity (74-76), which is 











B19 replication and its regulation 
            B19V replication takes place in the nucleus of the infected cells. The single-stranded 
genome of the virus is first converted to dsRF DNA. B19V genome (RF) contains two 67-bp (nt 
5214 - 5280) long minimum origin of replication (Ori) at both ends (77). Although the origins 
function independently, but both origins are required for the efficient DNA replication of the 
virus (78). B19V genome can replicate without inverted terminal repeats (ITR), however, ITRs 
significantly enhance viral DNA replication (78). Ori contains NS1 binding elements (NSBEs) 
(58), terminal resolution site (trs) (62), STAT5 binding site, and potential host factor binding 
sites (Fig. 1-4) (78). NS1 binds NSBEs and nicks DNA at trs (62), whereas STAT5 binds Ori 
and recruits MCM (Minichromosome Maintenance) complex (78). After NS1 nicking, DNA 
replication continues, and presumably follows rolling hairpin model of replication (Fig. 1-2), as 
suggested for other parvoviruses (79). Upon microarray analysis of dynamic transcriptome of 
B19V infected EPCs, we recently found that DNA metabolism, DNA replication, DNA repair, 
DNA damage response, cell cycle and cell cycle arrest pathways are significantly altered upon 
virus infection (80). Broadly, B19V replication is regulated by the following factors: 
I. EPO-signaling. 
            In response to low oxygen tension, human kidney interstitial fibroblasts secrete EPO, a 
glycoprotein cytokine that promotes the differentiation and development of erythroid progenitors 
that results in the production of mature RBCs (81). During erythropoiesis, pluripotent 
hematopoietic stem cells (HSCs, CD34+) are differentiated into enucleated erythrocytes, 
encompassing the following stages – BFU-Es, CFU-Es, normoblasts, erythroblasts, reticulocytes 
and finally the mature erythrocytes (81,82). The earlier stages of differentiation are EPO-
independent (82), and rely on factors like, stem cell factor (SCF) (83,84), IL-6 (85) and IL-3 
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(83). However, the late stage differentiation process requires EPO (82,86). The exclusive tropism 
of B19V for erythroid progenitor cells partly depends on the expression of receptor and co-
receptors on the cell surface and partly on the essential host cellular factors for efficient virus 
replication. Erythroid lineage cells depend on EPO for survival (87), but B19V also needs EPO 
for its replication (17).  BFU-Es and CFU-Es, the late stage erythroids, are highly susceptible to 
B19V infection (88). B19V-semi permissive cell lines (e.g. UT7/Epo-S1) depend on EPO for cell 
proliferation and survival. Interestingly, B19V-permissivity of these cell lines strictly depends on 
EPO (Fig. 1-2) (88). CD36+ EPCs differentiated from CD34+ in absence of EPO are not 
permissive to B19V infection and B19V genome replicates only in the presence of EPO and 
requires phosphorylated Janus kinase 2 (JAK2) (17). EPO binds EPO-receptor and activates 
ERK, Phosphoinositide 3-kinase (PI3K) and JAK2-STAT5 pathways (Fig. 1-2)  (89). JAK2-
STAT5 pathway is essential for B19V replication while the ERK pathway negatively regulates 
B19V replication and PI3K is dispensable for virus replication (18). Although EPO signaling 
activates ERK pathway, B19V inhibits the ERK pathway presumably through its 11-kDa protein 
(18,90). Therefore, B19V fine tunes the EPO-signaling that favors efficient virus replication. In 
order to understand the underlying mechanism of STAT5 dependent B19V replication, we 
demonstrate in chapter 2 that STAT5 phosphorylation is critical for B19V DNA replication (78). 
The viral Ori harbors a STAT5 binding site (Fig. 1-4) and phosphorylated STAT5 binds viral 
origins both in-vivo as well as in-vitro (78). The mutation of STAT5 binding site within viral 
origins completely abolishes viral DNA replication (78). Importantly, STAT5 interacts with 
MCM complex. The disruption of STAT5-Ori complex leads to decrease in virus DNA 
replication and the abundance of MCM complex decreased significantly at the viral Ori (78). 
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Therefore, our proposed model shows that B19V utilizes STAT5 interaction with viral Ori to 
recruit MCM complex for the initiation of viral DNA replication (78). 
II. Hypoxia. 
            During the propagation of B19V in ex-vivo expanded CD36+ EPCs, progeny virion 
production is not as efficient as under natural conditions in human bone marrow on B19V 
infection of EPCs. The viremia in B19V infected patients goes up to 1013 genomic copies per ml 
of plasma (91,92), which indicates the requirement of other factors in determining the production 
of virions. Oxygen tension is low in bone marrow (93) and lower oxygen pressure favors 
erythroid cell development in culture (94). Interestingly, B19V infected human EPCs at hypoxia 
(1% O2) enhances viral gene expression, viral replication, and virus production. Hypoxia 
augmentation of B19V replication is independent of PHD/HIFα pathway. Hypoxia also enabled 
the B19V-infected pluripotent erythroid cells (KU812F) to yield high progeny virions (95). 
Increase in the productive B19V infection under hypoxic conditions wasn’t due to increase in the 
B19V entry or intracellular trafficking of the virus and HIF-1 was shown not to play any role in 
hypoxia-induced enhancement in B19V infectivity (18). However, hypoxia regulates EPO/EPO-
receptor signaling pathway by upregulating STAT5 and downregulating MEK activation, 
thereby enhancing B19V DNA replication in both B19V-infected EPCs and M20 (infectious 
clone)-transfected UT7/Epo-S1cells (18). We strongly believe that upregulation of STAT5 and 
downregulation of MEK/ERK signaling during hypoxia promote virus replication.  The B19V 
infectious clone grows rapidly (~80 times) in UT7/Epo-S1 cells under hypoxia (18). The culture 
of EPCs or UT7/Epo-S1 cells under hypoxia for B19V propagation is currently the best culture 
system in use. The efficient replication of M20 infectious clone and the subsequent production of 
infectious virions holds promise to study B19V replication and the underlying mechanism(s) of 
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replication. Also, mutagenesis of B19V molecular clone M20 could help to understand the role 
of individual viral proteins and the specific protein domains in virus replication.  
III. Late S phase cell cycle. 
            B19V DNA replication is dependent on host cellular DNA replication, since the virus 
doesn’t encode a viral DNA polymerase (96). B19V induces cell cycle arrest in both virus-infected 
CD36+ EPCs and UT7/Epo-S1 or M20 transfected UT7/Epo-S1 cells at G2/M (14,68). Virus 
infected UT7/Epo-S1-arrested cells display 4N DNA content and (5’-bromo-2-deoxy-uridine) 
BrdU-pulse labeling for de novo DNA synthesis along with DAPI staining indicates that the cells 
are precisely in late-S phase (68). Upon B19V infection of UT7/Epo-S1, cyclin A, cyclin B1 and 
phosphorylated cell division cycle 2 (CDC2) were shown to accumulate and CDC2-cyclinB1 
complex displayed enhanced kinase activity (14). The sequestration of cyclin B1 to the cytoplasm 
in B19V-infected cells indicates that B19V somehow prevents its import to nucleus, thus results 
into cell cycle arrest at G2 phase (14). NS1 alone has been shown to induce a true G2/M cell cycle 
arrest, doesn’t show BrdU incorporation but displays 4N DNA content (68), and de-regulation of 
E2F family transcription factors have been implicated for such arrest (57).  
            While B19V induces DDR that promotes virus replication, virus-induced DDR is not 
involved in cell cycle arrest at G2/M (60). Like other autonomous parvoviruses, B19V infection 
also induces arrest at S phase (67,68). Therefore, B19V induced late S phase arrest is possibly an 
outcome of replication-induced S phase arrest and NS1-induced G2/M arrest. Various S phase 
replication factors like polymerase delta (pol δ), proliferating cell nuclear antigen (PCNA), 
replication factor C-subunit 1 (RFC-1), the MCM complex except the DNA repair DNA 
polymerases are actively recruited to viral replication centers with pol δ and pol α essential for 
viral DNA replication (68,80). It is likely that like other parvoviruses (97-99), B19V exploits the 
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cell cycle arrest at late S phase and uses S phase factors for viral DNA replication. In addition, 
replication protein A-32 (RPA32) also colocalizes with viral replicating machinery. Although 
phosphorylated RPA32 forms also show colocalization, phosphorylation itself seems dispensable 
for virus replication (80), supporting the observation that B19V uses S phase for genome 
amplification.  
IV. DNA damage response (DDR). 
            DNA damage response (DDR) is a cellular defense mechanism to preserve genomic 
stability and integrity in response to double strand breaks (DSBs), single strand DNA breaks, or 
installed replication (100). There are three major kinases (mediators) responsible for signaling 
downstream DDR effects, including Ataxia telangiectasia mutated (ATM), Ataxia telangiectasia 
and Rad3 related (ATR), and DNA dependent protein kinase, catalytic subunit (DNA-PKcs). 
Apart from recognizing the damaged cellular DNA, DDR is also activated by various DNA 
viruses either to combat the infection by invoking innate immune response or to facilitate viral 
DNA replication (96,101). B19V infection induces a DDR by activating all the three PI3K 
kinases (ATR, ATM and DNA-PKcs) (67). Phosphorylated ATM, ATR, DNA-PKcs and their 
downstream effectors (CHK1, CHK2 and Ku70/80) localize within the virus replication centers. 
Activated ATR and DNA-PKcs, but not ATM were found essential for B19V replication (60,67). 
Further, it was found that mere expression of the viral genes didn’t lead to the phosphorylation of 
RPA32 and γH2AX, a hallmark of DDR (60). Interestingly, NS1 itself phosphorylates ATR to 
induces cell cycle arrest, however, such activation of ATR doesn’t lead to phosphorylation of 
RPA32 and γH2AX (70). It was found that replicating, infectious clone-M20, but not a 
replication deficient M20 mutant, led to the induction of DDR (60), which implies that the 




            Infection with B19V is a global concern and has a seroprevalence against the virus that 
varies from region to region and between the different age groups. The seroprevalence among 
children below the age of 5 years is 2-20%, between the age group of 5-18 years 15-40% and 
among  adults 40-80%(1,102). The virus infection is contracted via inhalation, blood transfusion 
and from pregnant woman to fetus (103,104). It is still unknown how the virus penetrates the 
respiratory and placental barriers to reach the bone marrow and the fetal liver, respectively. The 
incubation time varies between 4-14 days, accompanied with prodromal symptoms like fever, 
headache, malaise and myalgia (1,105). After 2-3 weeks, the rash and joint symptoms become 
visible, which are believed to have an immunopathological origin (106). B19V is an etiological 
agent of erythema infectiosum, arthopathy, hydrops fetalis, transient aplastic crisis, and of a 
persistent infection in immunocompromised patients that causes pure red cell aplasia (PRCA) 
(1,107). Erythema infectiosum or “slapped cheek” is also called Fifth disease in children. 
Following the virus infection, the rashes appear first on the cheeks of the infected children as 
facial erythema, almost 18 days after infection, which then extend to trunk and proximal 
extremities as erythematous maculopapular eruptions (1,107,108). In adults, B19V causes 
arthralgia and arthritis, resembling rheumatoid arthritis and joint symptoms that can last for 
months post- infection (107,109). The parvovirus infection in pregnant women causes non-
immune hydrops fealis due to severe anemia in fetuses, which leads to miscarriage and 
intrauterine fetal death (1,110). Transient aplastic crisis was the first disease linked to B19V and 
is a direct outcome of virus mediated cytotoxicity of erythroid progenitor cells(107). The B19V 
infection in children also leads to thrombocytopenia and immune mediated neutropenia 
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(107,111). In addition, the virus infection is also associated with myocarditis, encephalitis, 
hepatitis, glomerulonephritis and nephrotic syndrome. (1,107).  
Productive infection of B19V induces cell cycle arrest and erythroid cell death. 
            B19V infection induces cell cycle arrest at G2 phase (14). Upon further analyses of the 
cell cycle during the virus infection, it was found that the arrest at G2 phase has 4N DNA content 
but also incorporates BrdU, a thymidine analog, suggesting that the infected cells are in late S 
phase (68). During early infection, the cells are precisely at late S phase, however, at the late 
phase of infection most infected cells are found in G2 phase (68). Interestingly, the expression of 
NS1 induces a true G2 arrest where cells don’t incorporate BrdU but only exhibit 4N DNA 
content (68). There are many players responsible for inducing cell cycle arrest during B19V 
infection. During the B19V induced cell cycle arrest of UT7/Epo-S1 cells, it was observed that 
nuclear import of CDC2/cyclin B1 is prevented (14). NS1 itself causes a true G2 arrest by 
importing the repressive E2F transcription factors (E2F4/E2F5) (57). A putative NS1 
transactivation domain-2 (TAD2) was found responsible for NS1-induced G2 arrest (60). 
Recently, the underlying mechanism of NS1 induced cell cycle arrest was explored in much 
detail (70). NS1-TAD2 domain transactivates several host genes that lead to the activation of 
ATR. Activated ATR phosphorylates cell division cycle 25C (CDC25C) at serine-216 through 
the activation of CHK1 (70). Phosphorylated CDC25C at S216 reduces its phosphatase activity 
and renders it complexed with 14-3-3 protein in the cytoplasm (112). As a result, inactive 
CDC25C is unable to dephosphorylate cyclin B1/CDK1 (pT14/Y15) complex to activate it. An 
active cyclin B1/CDK1 complex is essential for G2 to M transition (113). In NS1-expressing 
UT7/Epo-S1 cells, nuclear entry of cyclin B1/CDK1 complex is not hampered, rather the 
complex exhibits reduced kinase activity (70). Hence, B19V NS1 induces G2 arrest by activating 
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the ATR-CDC25C-CDK1 pathway (70).  NS1 activation of ATR doesn’t lead to the activation of 
γH2AX and RPA32, a hallmark of DDR (60,70). Moreover, DNA replication induced DDR and 
thereafter, activation of ATR leads to the arrest of cells at late S phase (68). It appears that NS1 
or DNA replication mediated activation of ATR transduce signaling through different 
downstream pathways and results in cells arrested at different phases of cell cycle. The last factor 
implicated in B19V infection induced cell cycle arrest is the viral genome itself. A nucleotide 
sequence 5’-GTTTTG T-3’ from the viral promoter region arrests BFU-E progenitor cells at S 
and G2/M phase. This promoter sequence is a CpG oligodoxynucleotide-2006 analog that is a 
ligand of toll-like receptor 9 (TLR9). It appears that viral genomic replication initially stalls 
infected cells at late S phase and later with the help of NS1 arrests at G2/M, which eventually 
leads to cell death. B19V infection specifically targets BFU-E and CFU-E progenitors (114), 
disrupts erythropoiesis and results in the transient aplastic crisis (115). The virus-induced cell 
death is apoptotic in nature and involves caspase-3/6/8 activation (65,116). B19V NS1 activates 
the extrinsic apoptotic pathway involving the TNF-α pathway in CD36+ EPCs or UT7/Epo cells 
(116). The B19V encoded 11-kDa protein is also implicated in causing cell death through 
apoptosis, which involves caspase-10 (71). It was found that 11-kDa is a more potent inducer of 
apoptosis than NS1 (71). 
Non-productive infection of B19V causes inflammatory diseases of various tissues.  
            Virus infection is seen in non-erythroid cells as well. The virus uses an alternative entry 
route by complexing with antibody and entering through complement factor C1q and C1q 
receptor mediated endocytosis (23). There is no clear evidence that B19V replicates or produces 
virions in any non-erythroid cell lineage, hence the infection is considered largely non-
productive.   
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            B19V predominantly infects endothelial cells of various tissues (e.g., aorta, umbilical 
vein and pulmonary arteria etc.) (23). Other cell lines infected include U937 cells (20), 
circulatory angiogenic cells (CACs) and CD34+KDR+ endothelial progenitor cells (21,22). B19V 
infection appears to be  persistent and viral genes are silenced through methylation of CpG sites 
on the DNA (117). Even after the infection is resolved, the viral DNA can be found in various 
tissues like spleen, liver, tonsils, testes and brain (19,118). 
            Upon infection, the infected tissue evokes host-cellular response against the virus which 
culminates in a several pathologies. B19V infection has been linked to several inflammatory 
diseases like cardiomyopathy, rheumatoid arthritis, hepatitis, vasculitis and meningoencephalitis 
(1,19). B19V infection or the expression of viral proteins can modulate the immune response. 
NS1 upregulates IFNAR1 and IL-2 (inflammatory response) and downregulates OAS1 and 
TYK2 (antiviral response) through the activation of STAT3/PIAS3 signaling pathway in human 
endothelial cells (HMEC-1) (119). The increase in the expression of inflammatory molecules 
like NF-κB, IL-6 and COX2 correlated with expression of viral capsid proteins in the colon, 
thyroid and synoviocytes (120-123). Particularly, in synoviocytes, VP1u phospholipase A2 
activity is implicated in the production of inflammatory response (121). NS1 induces apoptosis 
in hepatocytes through the activation of caspse-3 and caspase-9 (66,124).  In summary, B19V 
infection of non-erythroid tissues evokes inflammatory responses that lead to various 
pathologies.  However, with the exception of the placental endothelium (125), no other non-
erythroid cell type supports B19V multiplication. 
B19V induced immune responses 
         The virus infection elicits a strong humoral immune response (126). Initially, the IgM 
antibodies are produced followed by IgG after several days post-infection, which provide few 
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months to lifelong protection, respectively (106,126,127). The antibody response is directed 
against VP1 (74), VP2  (128), and the NS1 (129) proteins. However, the neutralizing antibodies 
produced are against VP1u, the N-terminal (1-80 aa) region of the VP1 protein (130). The CD8+ 
T cells response has also been observed in B19V infected patients, which sustains for several 
months even after the clearance of the virus (131). The T cell-mediated response is specifically 
directed against the VP1 and VP2 proteins, in which the antigen is presented to CD4+ T cell by 
class II molecules (132). Of note, the T cell response is of Th1 type and involves the release of 
IFN- γ, IL-2, IL-12, and IL-15 (133,134).  B19V-induced innate immune responses are not well 
established. There are few studies which show that the viral proteins (NS1 & VP2) regulate the 
expression of defensins, TLR-4/5/7/9 (135) and  TLR9 can recognize CpG ODN-2006, the P6 















Conclusion and future directions 
            It has been reported that almost 40-60% of the world’s population is infected with 
parvovirus B19 (137). However, such persistent infection is at sub-immunogenic levels, as viral 
load is kept under control by our immune system, particularly by neutralizing antibodies against 
B19V VP1u region. During times when patients are under immune suppression or infected with 
other pathogens, the viral load increases and causes extensive cell death of erythroid progenitor 
cells and leads to various inflammatory diseases as described above.  
            There is no specific treatment for B19V infection, except IVIG treatment or blood 
transfusion, so there is a need to develop antivirals for B19V infection. The new advancements 
in the field of B19V viral replication have identified various critical steps during the process of 
virus replication. One such important step is NS1 binding to the viral origin and subsequent 
nicking of B19V DNA at trs (58). Recently, in-vitro nicking assay for NS1 was developed (62), 
which could be utilized to screen for inhibitors of NS1 nicking. Furthermore, since the VP1u 
region is essential for viral entry, peptide analogs of VP1u (1-100) (31) or neutralizing 
monoclonal antibodies (138) against VP1u can be employed to check B19V entry. In chapter 2, 
our study demonstrated that STAT5 phosphorylation is essential for B19V DNA replication (78). 
Pimozide, a STAT5 inhibitor and an FDA-approved drug abolishes virus replication in CD36+ 
EPCs (78). Therefore, pimozide could be a potential drug for B19V infection and can be 
repurposed for B19 related pathologies and included in prophylactic anti-virals for transplant 
recipients. However, the development of new antivirals against B19V infection needs an animal 
model to validate any new treatment.  Currently, simian parvovirus (SPV) infection of 




Fig. 1-1. Transcription map of Parvovirus B19.  
(A) Linear ssDNA genome of B19V. The genome is flanked by two inverted terminal 
repeats (ITRs), containing unpaired and mismatched bases, shown as bulges and bubbles, 
respectively. (B) Double stranded replicative form of B19V genome. The viral promoter denoted 
as P6 transcribes a single precursor mRNA (pre-mRNA). Pre-mRNA has two donor sites (D1 & 
D2) and four acceptor sites (A1-1, A1-2, A2-1, and A2-2). Using alternative splicing and 
polyadenylation, pre-mRNA is processed into at least 12 different mRNAs (only R1-R9 shown 
here). Mature mRNAs polyadenylate at (pA)p or (pA)d sites. At least five different proteins are 
known to be encoded by different species of mRNA transcripts. Different colors indicate the use 
of different open reading frames for the translation of proteins. Question marks indicate mRNAs 
























Fig. 1-2. Proposed model of B19V life cycle.  
B19V infects human erythroid progenitor cells. The virus first interacts with globoside 
(Step 1) and undergoes a conformational change that exposes VP1u which subsequently binds an 
unknown co-receptor (Step 1). Thereupon, the virus is endocytosed and somehow escapes the 
lysosomal route and enters the nucleus (Step 3). Inside the nucleus, the virion uncoats and 
releases the ssDNA genome (Step 4). Using the 3’OH of the left ITR, the second strand is 
synthesized to form a functional origin of replication (Step 5). Next, EPO and hypoxia activates 
and increases pSTAT5, which interacts with MCM and then binds Ori region. NS1 binding to 
NS1BE is critical for nicking ssDNA at trs and for helicase activity (step 6). The nicking creates 
a new 3’ OH end to continue DNA replication that results into duplex replicative intermediate 
(Step 7). The dsDNA form also transcribes a single pre-mRNA that is processed into various 
mRNAs which are exported to cytoplasm for translation (Step 8). VP1/2 assemble into trimers to 
form capsids, which are transported back to the nucleus (Step 9). Through strand displacement, 
ssDNA is packaged into capsids, which probably requires NS1 (step 10). NS1 and 11-kDa in the 

























Figure 1-3. A diagram of NS1 functional domains. 
The N-terminus (amino acid 2-176) of NS1 possesses DNA binding and endonuclease 
activity. The endonuclease motif resides between amino acids 137 and 145. The central region of 
NS1 exhibits putative helicase activity. Transactivation activity is restricted to the C-terminus of 
NS1. NS1 carries two nuclear localizing signals, between amino acids 177-179 & 316-321 (NLS, 
in green). Three putative transactivation domains have been identified in the C-terminus of the 
NS1 protein: TAD1 (aa 416-424), TAD2 (aa 523-531), and TAD3 (aa 566-574). The central 
region also contains two NTP binding motifs between amino acids 323 to 378 and 367 to 378 





















    
 
          
  











Figure 1-4. A diagram of the B19V minimal origin of viral DNA replication (Ori).   
B19V has a 67-bp long minimum origin of DNA replication (Ori) at each end of the 
genome. Ori harbors two NS1 binding elements (NSBE1&2, in red), one STAT5 binding 
element (STAT5BE, in green), a terminal resolution site (trs, black), and two potential cellular 










































Figure 5. NS1 is a multi-functional protein. 
The B19V NS1 multimer binds the dsDNA form of the genome at NSBE1-2 via N-
terminus region (5-7), but nicks ssDNA at trs and covalently attaches to the 5’ end. NS1 induces 
a DNA damage response that is essential for virus replication. The virus replication process leads 
to the activation of ATR, ATM and DNA-PKcs. However, the activation of ATR and DNA-
PKcs, but not ATM, is essential for virus replication. NS1 transactivates its P6 promoter with the 
assistance of Sp1/Sp3. NS1 is a global transactivator and regulates ~1,700 genes. NS1 induces 
apoptosis through the activation of caspases 2/6/8 and TNF-α. The central region of NS1 protein 







































Chapter 2:  
Phosphorylated STAT5 Directly Facilitates Parvovirus B19 DNA Replication in Human 













                                                 
2 The chapter has been previously published in PLOS Pathogens: Ganaie, S. S., Zou, W., Xu, P., Deng, X., 
Kleiboeker, S., and Qiu, J. (2017) Phosphorylated STAT5 directly facilitates parvovirus B19 DNA replication in 







Productive infection of human parvovirus B19 (B19V) exhibits high tropism for burst forming 
unit erythroid (BFU-E) and colony forming unit erythroid (CFU-E) progenitor cells in human 
bone marrow and fetal liver. This exclusive restriction of the virus replication to human erythroid 
progenitor cells is partly due to the intracellular factors that are essential for viral DNA 
replication, including erythropoietin signaling. Efficient B19V replication also requires hypoxic 
conditions, which upregulate the signal transducer and activator of transcription 5 (STAT5) 
pathway, and phosphorylated STAT5 is essential for virus replication. In this study, our results 
revealed direct involvement of STAT5 in B19V DNA replication. Consensus STAT5-binding 
element was identified adjacent to the NS1-binding element within the minimal origins of viral 
DNA replication in the B19V genome. Phosphorylated STAT5 specifically interacted with viral 
DNA replication origins both in vivo and in vitro, and was actively recruited within the viral 
DNA replication centers. Notably, STAT5 interacted with minichromosome maintenance 
(MCM) complex, suggesting that STAT5 directly facilitates viral DNA replication by recruiting 
the helicase complex of the cellular DNA replication machinery to viral DNA replication centers. 
The FDA-approved drug pimozide dephosphorylates STAT5, and it inhibited B19V replication 
in ex vivo expanded human erythroid progenitors. Our results demonstrated that pimozide could 









Human parvovirus B19 is a small, non-enveloped parvovirus with a single-stranded (ss) 
DNA genome of 5.6 kb. It belongs to the genus Erythroparvovirus of the Parvoviridae family 
(140). The B19V genome is flanked by identical inverted terminal repeats (ITRs) at both ends 
(141). B19V is pathogenic to humans and causes a myriad of pathologies, including fifth disease 
in children, transient aplastic crisis, persistent anemia in immune-compromised patients, hydrops 
fetalis in pregnant women, and arthropathy (1,142-145). B19V infects human erythroid 
progenitor cells through initial attachment to its primary receptor (P-antigen) (24) and interaction 
with co-receptors, resulting in virus internalization (27,31). Virus replication and assembly take 
place in the nuclei of infected cells. The B19V double-stranded (ds) replicative form (RF) 
genome expresses the large non-structural NS1 protein, two small non-structural proteins (the 
11-kDa and 7.5-kDa proteins), and two capsid proteins (VP1 and VP2) (43,46,47) 
B19V infects human EPCs during the late stages of maturation, particularly burst forming 
unit-erythroid (BFU-E) cells and colony forming unit-erythroid (CFU-E) cells (3-5,115). B19V 
also infects non-erythroid tissues (21-23), but the infection of these tissues is non-productive, as 
virus replication is not fully supported (19,21,96). Erythropoietin (EPO), a hormone secreted by 
renal tissue in response to hypoxia, is essential for survival, differentiation, and development of 
EPCs during the late maturation stages (87). In addition to the role in survivability of EPCs, 
EPO/EPO receptor (EPO-R) signaling is essential to B19V replication (17). EPO binding to 
EPO-R activates Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5 
(STAT5), phosphoinositide 3-kinase (PI3K), and extracellular signal-regulated kinase (ERK) 
pathways. The JAK2-STAT5 pathway positively regulates B19V replication, the ERK pathway 
negatively regulates B19V replication, and the PI3K pathway is dispensable to B19V replication 
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(18) . Expression of STAT5A is upregulated during hypoxia, and replication of B19V in human 
EPCs is facilitated by hypoxic conditions (18). JAK2 predominantly phosphorylates STAT5A in 
the cells of erythroid lineage (89), and thus STAT5A is largely involved in facilitating B19V 
replication of EPCs under hypoxic conditions (18). The disease outcomes of hematological 
disorders caused by B19V infections result from the death of infected human EPCs. B19V 
infection inhibits erythropoiesis by inducing cell-cycle arrest (57,60,70), and eventually results in 
apoptosis (65,71,116,146). 
The results of this study confirmed that phosphorylation of STAT5 is essential for B19V 
DNA replication. Mechanistically, the B19V RF DNA genome harbors STAT5-binding element 
(STAT5BE) within the minimal origins of DNA replication (Ori), located to the ITRs at each 
end of the viral genome. The binding site specifically binds phosphorylated STAT5 (pSTAT5). 
Moreover, our experiments revealed a novel interaction between STAT5 and minichromosome 
maintenance (MCM) complex; B19V exploits this interaction to recruit MCM complex to the 












Materials and Methods 
Ethics statement. 
We purchased CD34+ hematopoietic stem cells, which were isolated from bone marrow 
of a healthy human donor, from AllCells LLC (Alameda, CA) without any identification 
information on the cells, and, therefore, an institutional review board (IRB) review was waived. 
Primary cells and cell lines. 
Primary human CD36+ EPCs were expanded ex vivo from CD34+ hematopoietic stem 
cells as previously described (17,18,147). Briefly, hematopoietic CD34+ stem cells, purchased 
from AllCells, LLC (Alameda, CA), were grown in Wong medium under normoxia up to Day 4 
and frozen in liquid nitrogen (18). In each experiment, Day 4 cells were thawed and grown under 
normoxia in an atmosphere containing 5% CO2 and 21% O2 at 37ºC for 2-3 days, prior to 
incubation under hypoxia at 5% CO2 and 1% O2.  
The megakaryoblastoid cell line, UT7/Epo-S1, was cultured in Dulbecco's modified 
Eagle’s medium with 10% fetal bovine serum and 2 U/ml of EPO (Amgen, Thousand Oaks, CA) 
in 5% CO2 and 21% O2 at 37ºC (14,77). A UT7/Epo-S1 cell line expressing B19V NS1 protein 
(NS1-S1) was cultured under the same conditions, except that 5 µg/ml doxycycline was used to 
induce NS1 expression when needed (70).   
Virus and infection. 
            Plasma samples containing B19V at ~1 × 1012 viral genomic copies per ml (vgc/ml) were 
obtained from ViraCor Eurofins Laboratories (Lee’s Summit, MO). After 2 days of hypoxia, 
CD36+ EPCs were infected with B19V at a multiplicity of infection (MOI) of ~1,000 vgc per 





STAT5-SH2 Inhibitor (STAT5-SH2i, CAS 285986-31-4; catalog number (cat#) 573108), 
a cell-permeable compound that selectively targets the SH2 domain of STAT5 (148), and STAT5 
Inhibitor III, pimozide (CAS 2062-78-4, cat# 573110), which dephosphorylates STAT5 (149), 
were purchased from EMD Millipore (Billerica, MA). Both chemicals were dissolved in DMSO 
to produce stock solutions (at 100mM) that were kept at -80 ºC. 
Proximity ligation assay. 
Duo link In-Situ Red Mouse/Rabbit kit (cat# DUO92101) was purchased from 
MilliporeSigma (St Louis, MO). Proximity ligation assay was performed following the 
manufacturer’s instructions, as described previously (150).   
Immunofluorescence assay and confocal imaging. 
Immunofluorescence assay was carried out as described previously (18,68). Briefly, 
infected EPCs were deposited on slides by cytospinning, fixed with 3.7% paraformaldehyde for 
30 min, and permeabilized with phosphate-buffered saline (PBS, pH7.2) containing 0.5% Triton 
X-100 (PBS-T) for 5 min at room temperature. Non-specific interactions were blocked with 3% 
bovine serum albumin (BSA) before subsequent incubation with primary and fluorescence-
labelled secondary antibodies. The slides were visualized with a Nikon confocal microscope, and 
images were taken at 100 × magnification.  
Plasmid construction. 
pM20 contains the full-length B19V replicative from (RF) genome (nt 1-5596), and pN8 
contains a half-ITR deleted B19 RF genome (nt 199-5410) (77,151). They are diagramed in Fig 
2-2A. pN8mOriL and pN8mOriR were constructed by mutating the STAT5BE of the Ori in the left 
and right half ITRs of the pN8, respectively. Both STAT5BE were mutated in pM20 and pN8 
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resulted in pM20mOri and pN8mOri, respectively, which are diagramed with mOri shown, and the 
sequence of mutated Ori in the half right ITR is depicted (Fig 2-6A).    
Transfection. 
UT7/Epo-S1 cells were electroporated in V solution using Amaxa Nucleofector (Lonza, 
Basel, Switzerland), as described previously (18). Briefly, B19V infectious clone pM20 or 
mutants were enzymatically digested with Sal I. The linearized DNA was gel-purified. 2 µg of 
DNA was used for electroporation of 2 × 106 cells. After transfection, UT7/Epo-S1 cells were 
cultured under hypoxia of 1% O2.  
Flow cytometry and cell-cycle analysis. 
B19V-infected CD36+ EPCs were examined for virus infection by flow cytometry 
analysis with an anti-B19V capsid antibody, as described previously (18,68). For cell-cycle 
analysis, a bromodeoxyuridine (BrdU) incorporation assay was used, as described previously 
(68).  
Southern blot analysis. 
Lower molecular DNA (Hirt DNA) was extracted from either B19V-infected CD36+ 
EPCs or transfected UT7/Epo-S1 cells by a Hirt extraction method, as described previously (49). 
Hirt DNA extracted from UT7/Epo-S1 cells was further digested with Dpn I to remove non-
replicated plasmid DNA input. Southern blot analysis was performed as reported previously 
(49,60). B19V RF DNA M20 excised from pM20 with Sal I was used as a probe.  
Phosphorylated STAT5 protein purification. 
A biotinylated dsDNA probe (152), 5’-Bio-GAT ACT AGT TTC GTG GAA TCG TGG 
CAC TAT GAA CCA-3’, containing a STAT5BE (underlined), was synthesized by IDT 
(Coralville, IA) and used to purify pSTAT5, following a published protocol (153) with some 
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modifications. Briefly, UT7/Epo-S1 cells grown in 14 dishes of 145 mm diameter were 
collected, washed with PBS, and resuspended in(70) Lysis Buffer-1 (10 mM HEPES, pH 7.6, 0.1 
mM EDTA, 1 mM DTT, 0.5% NP-40, 10 mM KCl, 0.5 mM PMSF, and protease inhibitor 
cocktail (PIC, MillopreSigma) for 5 min on ice. After vortexing, the lysate was centrifuged at 
500 × g for 5 min at 4ºC, and the nuclear pellet was washed with Lysis Buffer-1 without NP-40. 
The pellet was resuspended again in Lysis Buffer-2 (50 mM Tris, pH 7.6, 150 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 1 mM DTT, and 1 mM PMSF, and PIC), vortexed, and kept on ice for 
30 min. The nuclear lysate was sonicated, centrifuged at 12,000 × g for 20 min, and then passed 
through a 0.45 µm filter before being mixed with streptavidin beads pre-bound with the biotin-
dsDNA probe and incubated for several hours. The beads were then washed in Wash Buffer (50 
mM Tris-HCl, pH 7.6, 150 mM NaCl, 3-4 µg/ml poly dI-dC (MilliporeSigma), 1 mM PMSF, 
and PIC). Bound proteins were eluted in Wash Buffer with increasing salt concentrations (0.3 – 1 
M NaCl). The fractions containing pSTAT5 were identified by Western blotting.   
Electrophoretic mobility shift assay (EMSA).  
Electrophoretic mobility shift assay (EMSA) was performed as previously reported (154). 
Complementary forward and reverse oligonucleotides (synthesized at IDT, Coralville, IA) were 
annealed to form dsDNA probes, wt-Ori-39 and mut-Ori-39 that had the STAT5BE mutated 
(152) (Fig 2-2B). The probes were 5’ end labeled with 32P using [γ-32P] ATP.  Each 20 µl 
binding reaction contained 3 µg/ml of poly dI-dC (MilliporeSigma). 
Chromatin immunoprecipitation (ChIP) assay.  
Chromatin immunoprecipitation (ChIP) assay was performed essentially as described 
previously (155,156) with modifications. Cells were fixed in 1% formaldehyde for 10 min at 
room temperature and then quenched in 125 mM glycine. Fixed cells were washed with PBS, 
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and then lysed in 400 µl of Lysis Buffer (10 mM Tris-HCl, pH 8.0, 10 mM NaCl, 0.2 % NP-40, 
1 mM PMSF, and PIC) and incubated for 10 min on ice. After centrifugation at 2,500 rpm for 5 
min at 4ºC, the nuclear pellet was resuspended in 100 µl of Nuclear Lysis Buffer (50 mM Tris-
HCl, pH 8.1,10 mM EDTA, 1% SDS, and PIC) for 10 min on ice. One ml IP Dilution Buffer (20 
mM Tris-HCl, pH 8.1, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, and 0.01% SDS) was 
added, and chromatin was sheared by sonication at 80% power for 10 cycles of 15 s pulse and 1 
min rest. Sonicated samples were centrifuged to remove debris, and the supernatant was split 
aliquots. Antibody (2.5 µg) was added to each aliquot, and the mixtures were incubated 
overnight at 4°C. For each sample, 10 µg of yeast tRNA was added to 40 µl of cold PBS-
prewashed Protein A/G beads (Gold BioTechnology, Inc., St Louis, MO), and this mixture was 
added to the sample containing antibody and incubated with rocking for 6 h. Beads were 
collected by centrifugation  and washed with IP Wash-1 (20 mM Tris, pH 8.1, 2 mM EDTA, 50 
mM/500mM NaCl, 1% Triton X-100, 0.1% SDS) three times (first at low salt of 50 mM and then 
twice at 500 mM) for 10 min each at 4°C, followed by one wash with IP Wash-2 (10 mM Tris, 
pH 8.1, 1 mM EDTA, 0.25 M LiCl, 1% NP-40, and 1% deoxycholic acid) for 10 min at 4°C. The 
beads were then washed with cold TE, and protein-DNA complexes were eluted twice using 200 
µl of Elution Buffer (100 mM sodium bicarbonate and 1% SDS) for 10 min at room temperature. 
Crosslinking was reversed by addition of 16 µl of 5 M NaCl and incubation at 65°C. DNA was 
purified with a Qiagen PCR purification kit (Qiagen, Hilden, Germany), and ChIP product was 
recovered in 50 µl of H2O, and used for PCR or quantitative PCR (qPCR) analysis. 
 PCR or qPCR analysis. 
Immunoprecipitated viral DNA from ChIP assay was subjected to PCR analysis using 
either F1 and R1 or F1 and R2 primers spanning the viral origin region: F1 (nt 5036-5053), 5’-
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CCT GCC CCC TCC TAT ACC-3’, R1 (nt 5308-5285), 5’-CAG GAA ATG ACG TAA TTG 
TCC GCC-3’, and R2 (nt 5393-5376), 5’-ACG TCA ACC CCA AGC GCT-3’. q-PCR analysis 
was done as described previously (17), using the following primers: F (nt 353-378), 5’-GCA 
TCT GAT TTG GTG TCT TCT TTT AA-3’, R (421-403), 5’-TGG CTG CCC ATT TGC ATA 
A-3, and probe (nt 386-401), 5’ FAM-CGG GCT TTT TTC CCG C/IABkFQ-3’.   
Colony formation assay.  
The colony formation assay was performed with methyl cellulose-based medium (R&D 
Systems, Minneapolis, MN) according to the manufacturer’s instructions, with modifications. 
Briefly, CD36+ EPCs were cultured in Wong expansion medium and were treated with pimozide 
at various concentrations on Day 7. After 48 hours, ≥3 × 104 cells from each well were cultured 
in semi-solid methyl cellulose-based medium for 10-12 days, at which time colony counts were 
assessed by someone who was blinded to the experimental conditions. 
Immunoprecipitation assay and Western blotting. 
Co-immunoprecipitation (Co-IP) assay was performed as previously described (154,157). 
Briefly, UT7/Epo-S1 cells were collected, washed with PBS, and lysed in 
radioimmunoprecipitation assay (RIPA) buffer. After centrifugation at 12,000 rpm for 20 min at 
4°C, supernatant was taken and split into aliquots. Each aliquot was incubated with 3 µg of an 
antibody of interest overnight at 4°C, and then 40 µl of Protein A/G beads (washed with ice-cold 
PBS three times beforehand) was added, followed by incubation for 6 h. The beads were 
collected by centrifugation and washed three to five times with 1 × PBS, and then resuspended in 
1 × Laemmli sample buffer. Samples were boiled for 10 min and run on 10% SDS-
polyacrylamide gels for Western blot analysis, which was performed as described previously 
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(18,68,158). Pull-down assay was performed similarly to Co-IP, except that anti-Flag-conjugated 
beads or control beads were used.  
Antibodies.   
The following primary antibodies were purchased: mouse anti-STAT5 (cat# sc-74442), 
rabbit anti-STAT5 (cat# sc-835), anti-STAT5A (cat# sc-271542) and anti-STAT5B (cat# sc-
1656), anti-BrdU (IIB5) (cat# sc-32323) were from Santa Cruz (Dallas, TX); anti-MCM2 (cat# 
12079), and anti-pSTAT5(Y694) (cat# 4322) were from Cell Signaling (Danvers, MA); anti-
STAT5a/b pan-specific antibody (cat # AF2168) and normal IgG rabbit (cat# AB-105-C) were 
from R&D Systems Inc (Minneapolis, MN); anti-MCM5 antibody (cat# 2380-1) was from 
Epitomics (Burlingame, CA);  anti-B19V capsid (cat# Mab8293) was from Millipore (Billerica, 
MA); anti-BrdU (clone B44) was from BD (Franklin Lakes, NJ); and anti-β-actin (cat# A5441) 
was from Sigma; anti-MCM3 (cat# A300-124A), anti-MCM5 (cat# A300-195A; for ChIP), and 
MCM7(cat#A300-128A) were from Bethyl Laboratories (Montgomery, TX); anti-ATM(pS1981) 
(cat#ab81292) were from Abcam (Cambridge, MA); and anti-ATR(pT1989) (cat#GTX128145) 
from GeneTex (Irvine, CA). Rat anti-NS1 polyclonal antibody was prepared in our lab as 
previously reported (18).    
Horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit secondary 
antibodies were purchased from Sigma, and fluorescein isothiocyanate (FITC)-, Texas Red-, and 
Dylight405-conjugated anti-mouse, anti-rat, and anti-rabbit secondary antibodies were all 
purchased from Jackson ImmunoResearch (West Grove, PA). 
Statistics. 
Statistical analysis was performed using GraphPad Prism Version 7.0. Statistical 
significance was determined by using 1-way ANOVA analysis, followed by Tukey-Kramer post-
42 
 
test for comparison of three or more groups and unpaired (Student) t-test for comparison of two 

























Inhibition of STAT5 phosphorylation completely inhibited B19V DNA replication. 
Our results previously demonstrated that pSTAT5A has a critical role in B19V infection 
of human EPCs cultured under hypoxic conditions (18), leading us to consider in this study 
whether specific inhibition of STAT5 phosphorylation affects B19V replication. This possibility 
was tested by treating cells with a specific inhibitor of STAT5 phosphorylation, pimozide (149). 
At a final concentration of 15 µM, pimozide abolished >90% of the STAT5 phosphorylation in 
CD36+ EPCs, without altering the total expression of STAT5 (Fig 2-1A, lane 4). CD36+ EPCs 
were incubated with pimozide 6 h prior to infection, and, at 48 h post-infection, numbers of 
B19V-infected (capsid-expressing) cells were reduced by 4.7-fold and 18.5-fold at 15 μM and 25 
μM pimozide, respectively, compared with DMSO-treated cells (Fig 2-1B). Pimozide abolished 
viral DNA replication at both concentrations (Fig 2-1C). STAT5 dephosphorylation was 
confirmed in pimozide-applied infected cells (Fig 2-1D). These results suggested that inhibition 
of STAT5 phosphorylation abolishes viral DNA replication in B19V-infected CD36+ EPCs. 
Notably, treatment with pimozide at 15 µM did not significantly inhibit cell proliferation, as 
assessed by the BrdU incorporation assay (Fig 2-1E&F).  
Pimozide treatment, at a concentration as low as 10 μM, also abolished DNA replication 
of the B19V RF genome M20 in transfected UT7/Epo-S1 cells (Fig 2-10A, lane 3), and inhibited 
STAT5 phosphorylation (Fig 2-10B, lane 3). As controls, at 10 or 20 μM pimozide, cell 
proliferation was not significantly affected (2-10C&D Fig). Taken together, our results 




Phosphorylated STAT5 interacts with a consensus STAT5-binding element in the B19V 
minimal replication origin (Ori).  
The requirement of pSTAT5 for B19V DNA replication suggested that there might be a 
direct involvement of pSTAT5 in viral DNA replication. In silico analysis of the B19V genome 
demonstrated the presence of several consensus STAT5-binding elements (STAT5BEs) 
throughout the genome. STAT transcription factor binds a GAS or GAS-like motif with a 
consensus sequence of TTCN3GAA, TTCN3TAA, or TTAN3GAA (159). TTCN3TAA binds 
STAT5 (160) and is one of the top ten STAT5BEs identified in a genome wide analysis by ChIP-
seq (161). A consensus STAT5BE is located within the previously identified 67-nt Ori in the 
B19V genome (Fig 2-2A) (77).   
Binding of pSTAT5 from nuclear lysates of UT7/Epo-S1 cells to the STAT5BE in the 
Ori was confirmed by EMSA. A shifted band, indicating binding of protein to the probe, was 
observed in the presence of wild-type (wt) Ori-derived probe wt-Ori-39, but not the mut-Ori-39 
that has the STAT5BE mutated (Fig 2-2B, and Fig 2-2C, lanes 2 vs 3). On incubation with an 
anti-pSTAT5 antibody, the level of shifted band was dramatically decreased (Fig 2-2D, lane 3). 
Because the EMSA was performed in the presence of excess amounts of non-specific competitor 
poly dI-dC, these results indicated specific binding of pSTAT5 to the B19V Ori.  
pSTAT5 was purified from UT7/Epo-S1 cells by the use of beads conjugated with high 
affinity STAT5-binding DNA oligonucleotides (Fig 2-2E). EMSA was repeated with the 
purified pSTAT5, which shifted the labeled wt-Ori-39, but not the mut-Ori-39 (Fig 2-2F, lanes 2 
vs 3). Shifting of wt-Ori-39 was abolished by addition of the STAT5-SH2 inhibitor, STAT5-
SH2i, in a dose-dependent manner (Fig 2-2G, lanes 4-6). These binding assays confirm that 
pSTAT5 specifically binds to the STAT5BE of B19V Ori in vitro.  
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Phosphorylated STAT5 is associated with replicating viral DNA in the viral DNA 
replication centers of B19V-infected EPCs.  
The association of STAT5 with B19V NS1 and the viral capsid was demonstrated by 
immunofluorescence assays (Fig 2-3A&B). STAT5 colocalized with NS1 and the viral capsid in 
the nucleus of B19V-infected CD36+ EPCs. The association of STAT5 with viral capsid was 
confirmed by the observation of fluorescent foci in B19V-infected cells in a proximity ligation 
assay (Fig 2-3C), which produces an amplified signal when two labeled molecules are within 20 
nm of one another (162).  
Proximity ligation assay (Fig 2-3D) and confocal microscopy (Fig 2-3F) both 
demonstrated that STAT5 colocalized with replicating viral DNA that was pulse-labelled with 
BrdU in B19V-infected CD36+ EPCs, which are parvovirus replication centers (163,164) as 
shown by proximity ligation assay using anti-BrdU and anti-capsid antibodies (Fig. 2-3E). 
Interaction of pSTAT5 with the viral genome in cells was confirmed by ChIP assays in B19V-
infected CD36+ EPCs and M20-transfected UT7/Epo-S1 cells. The pSTAT5-DNA complexes 
were pulled down with anti-pSTAT5(Y694) antibody, and bound viral Ori was detected by PCR. 
In the ChIP assay, cellular DNA was sheared to < 500 bp by sonication (Fig 2-4A). A specific 
PCR band was amplified in samples from B19V-infected or M20-transfected cells pulled down 
by anti-pSTAT5(Y694) (Fig 2-4B, lane 4). Moreover, in UT7/Epo-S1 cells transfected with the 
B19V RF genome (M20), we observed that application of pimozide significantly decreased the 
amount of the Ori-containing fragments of the M20, as assessed by the quantitative ChIP assay 
targeting Ori (Fig 2-13C, Pimozide). Thus, these results confirmed the association of pSTAT5 




Disruption of the interaction between STAT5 and viral Ori inhibits viral DNA replication.   
A small molecule STAT5-SH2 inhibitor (STAT5-SH2i, CAS no. 285986-31-4) 
specifically targets the SH2 domain of STAT5 and inhibits STAT5 binding to DNA (148). 
EMSA was performed to determine whether STAT5-SH2i disrupts the interaction between the 
STAT5 and B19V Ori. Incubation of either UT7/Epo-S1 nuclear lysates or purified pSTAT5 
with increasing concentrations of the inhibitor showed that the STAT5-SH2i prevented 
formation of the STAT5-DNA formation in a dose-dependent manner (Fig 2-5A and Fig 2-2G). 
To examine the effect of the inhibitor on virus replication, CD36+ EPCs were pretreated with 
STAT5-SH2i 6 h prior to infection with B19V. The results showed that, at a final concentration 
of 500 μM, the inhibitor significantly decreased the virus-infected cell population by 10.7-fold 
(Fig 2-5B), and the level of viral RF DNA by ~10-fold (Fig 2-5C), but not the expression level 
of pSTAT5 (Fig. 2-5D), compared with the cells with DMSO treatment. Cell proliferation was 
not significantly affected by this level of inhibitor in mock-infected CD36+ EPCs (Fig 2-5E&F). 
The inhibition of viral DNA replication by STAT5-SH2i was also demonstrated in M20-
transfected UT7/Epo-S1 cells (Fig 2-11), and STAT5-SH2i significantly disrupted the 
interaction of pSTAT5 with the Ori of the B19V RF genome (M20) in vivo as shown by a ChIP 
assay (Fig 2-13C, STAT5-SH2i).     
Derivatives of B19V replicative form genome with mutated STAT5-binding elements do 
not replicate in UT7/Epo-S1 cells.  
The effect of mutation of the STAT5BE of the viral Ori on replication of the B19V RF 
genome was determined. The viral genome has an Ori sequence adjacent to each ITR, and the 
STAT5BE was mutated in either the left ITR (N8mOriL) or right ITR (N8mOriR) or both ITRs 
(N8mOri) of the N8 replicating RF DNA that has half ITRs at both ends, as shown in Fig 2-6A. 
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The replication capability of these mutated RF genomes was examined in UT7/Epo-S1 cells. 
Although the N8 RF DNA replicated well, much less replication occurred with N8mOriL and 
N8mOriR, and no replication was observed with N8mOri (Fig 2-6B). The mutations in the 
STAT5BEs were then introduced into both ITRs of M20 RF genome, to make the M20mOri 
mutant. No viral DNA replication was observed in M20mOri-transfected cells (Fig 2-6C, lane 2). 
Although both M20 and M20mOri RF genomes expressed NS1, viral capsid (a hallmark of B19V 
DNA replication (49) was present only in M20-transfected cells (Fig 2-6D).   
pSTAT5 interacts with the MCM complex of the pre-initiation complex of cellular DNA 
replication. 
During initiation of cellular DNA replication, the origin recognition complex (ORC) 
binds to autonomously replicating sequence sites and recruits cell division control protein 
(CDC6) and DNA replication factor CDT1 to replication origins (165). CDT1 recruits the MCM 
complex and primes replication initiation (166). Although viral DNA replicates independently of 
ORC/CDC6/CDT1, DNA viruses may require the MCM complex to initiate viral DNA 
replication (167). In the parvovirus adeno-associated virus (AAV), MCM complex is required for 
in vitro reconstitution of viral DNA replication (168). In the case of B19V, we previously found 
that MCM complex is associated with the viral DNA replication centers and has a role in B19V 
replication (68).   
Initially, to determine whether the viral NS1 protein has a role in recruitment of the 
MCM complex to the viral replication origin, we performed pull-down assays using lysates from 
NS1-expressing UT7/Epo-S1 cells. With pull-down of NS1, MCM and pSTAT5 were not 
detected (Fig 2-7A, lane 3), but the positive control transcription factor E2F5 [which interacts 
with B19V NS1 (57)] was detected, which suggested that NS1 has no role in recruitment of the 
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MCM complex. By contrast, co-immunoprecipitation (Co-IP) with an anti-pSTAT5 antibody 
pulled down MCM5 protein of the MCM complex from lysates of UT7/Epo-S1 cells (Fig 2-7B). 
Similarly, Co-IP with an anti-MCM5 antibody pulled down pSTAT5, in addition to MCM2 (Fig 
2-7C). The interaction between pSTAT5 and the MCM complex was DNA-independent, as 
DNase treatment of the lysate did not disrupt the interaction (Fig 2-7D, lane 4). Also, we show 
that MCM2, MCM3, MCM5 and MCM7 were associated with viral Ori in M20-transfected 
UT7/Epo-S1 cells, as confirmed by ChIP analyses (Fig 2-13A).   
STAT5 and the MCM complex colocalized in CD36+ EPCs, irrespective of whether the 
cells were infected (Fig 2-7E). An association of the MCM complex with STAT5 was confirmed 
in both B19V- and mock-infected cells by the proximity ligation assay (Fig 2-7F). This 
association was blocked by treatment of pimozide in CD36+ EPCs (Fig 2-7G). 
Immunofluorescence detection of the viral capsid demonstrated that, following B19V infection, 
most of the cells were infected (Fig 2-7H).  
pSTAT5 recruits MCM complex to B19V Ori to facilitate initiation of viral DNA 
replication. 
Our demonstration that pSTAT5 interacts with viral Ori as well as the MCM complex 
suggested that B19V might exploit these interactions to initiate viral DNA replication. To test 
this hypothesis, we infected CD36+ EPCs with B19V, and at 36 h post-infection (when B19V 
DNA replication was at its peak), we treated the cells with STAT5-SH2i (Fig 2-8A). At 6 h post-
treatment, the cells were collected for ChIP assay with anti-MCM2 antibody, which showed that 
MCM abundance on viral Ori decreased significantly in the presence of STAT5-SH2i, compared 
with untreated control cells (Fig 2-8B). Results with three-color confocal imaging demonstrated 
that MCM2 and STAT5 colocalized in mock-infected cells (in the absence of viral NS1) (Fig 2-
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8C, Mock). In infected cells, viral NS1 (which binds viral Ori) colocalized with both STAT5 and 
MCM, indicating that they were localized at the viral DNA replication centers (Fig 2-8C, 
B19V). These results suggested that B19V utilizes viral Ori-STAT5 and STAT5-MCM 
interactions to recruit the MCM complex to viral DNA replication origins, to initiate viral DNA 
replication. 
Pimozide is a promising candidate for the treatment of B19V infection. 
  To confirm the efficacy of pimozide as a drug, we treated primary CD36+ EPCs with 
pimozide at various concentrations, and infected them with B19V. The cells were collected 48 h 
post-infection for quantification of viral DNA replication (RF DNA) by Southern blot analysis, 
which demonstrated that the IC50 of pimozide for inhibition of viral DNA replication (the 
concentration at which 50% of viral DNA replication was inhibited) was 2.7 ± 0.69 µM (mean ± 
standard error) (Fig 2-9A). To examine the effect of pimozide on colony formation in the 
absence of virus infection, CD36+ EPCs were incubated with pimozide at increasing 
concentrations on Day 7 for 2 days, and then cultured in methyl cellulose-based medium for 
colony formation. After 10 days, numbers of colonies were counted (Fig 2-9B). Pimozide only 
moderately reduced the numbers of colonies at higher concentrations (10-25 µM), but it did not 










We have now demonstrated that STAT5 is directly involved in B19V DNA replication. 
Importantly, STAT5 specifically interacts with the MCM complex, the eukaryotic DNA helicase 
complex that is required for the formation and elongation of the cellular DNA replication fork 
(169). We therefore propose a novel model of B19V DNA replication in human EPCs, in which 
STAT5 functions as a mediator protein that brings the MCM complex to the viral DNA 
replication origins. Our results also identify pSTAT5 as a target for inhibition of B19V infection. 
In addition, as the STAT5-MCM interaction is independent of infection, we envisage an 
important role of this interaction in the context of cellular replication and transcription in human 
EPCs, which warrants further investigation. 
Phosphorylated STAT5A is directly involved in B19V replication.  
            STAT5 is phosphorylated at a single conserved tyrosine residue (Tyr694 in STAT5A and 
Tyr699 in STAT5B), and these phosphotyrosine motifs, upon intermolecular interaction, enable 
formation of either homodimers or heterodimers of STAT5A/B (170,171). These dimers 
accumulate in the nucleus and bind DNA, to transactivate target genes (170). EPO-activated 
JAK2 phosphorylates STAT5 in human EPCs (172). We examined the relative expression of 
STAT5A and STAT5B in UT7/Epo-S1 and CD36+ EPC lysates with a STAT5A/B pan-specific 
antibody, and found that STAT5A was predominantly expressed in both cell types (Fig. 2-12A). 
This result agrees with the observations that JAK2 kinase predominantly phosphorylates 
STAT5A in cells of erythroid lineage (89), and a constitutively phosphorylated STAT5A (1*6) 
variant enhances virus replication, whereas knockdown of STAT5A inhibits virus replication in 
B19V-infected EPCs (18).   
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STAT5B promotes viral DNA replication, but, during replication of human 
papillomavirus 16 (HPV16), STAT5B enhances viral DNA replication indirectly via regulation 
of TopBP1 expression, leading to the activation of ATR kinase (173). In a proof-of-concept 
experiment, fusion of STAT5BEs to the DNA replication origin of polyomavirus replicon DNA 
improved replication efficiency in transfected mouse lymphoid BA/F3 cells, corroborating the 
direct role of STAT5 in viral DNA replication (174). CD36+ EPCs have to be cultured in the 
presence of EPO for proliferation and differentiation (17), which dominantly leads activation of 
STAT5A (Fig. 2-12A) through the EPO-JAK2-STAT5 pathway (18); however, a DDR or 
activation of ATR is not observed in normal (uninfected) CD36+ EPCs (67,70) (Fig. 2-14A). 
Furthermore, in hydroxyurea-treated CD36+ EPCs, both ATR and ATM were activated; 
however, application of pimozide did not change the level of phosphorylated ATR or ATM 
(Fig.2-14A). As ATR activation enhances B19V replication (67), these lines of evidence suggest 
that pSTAT5 does not utilize the STAT5-ATR pathway to facilitate B19V replication in CD36+ 
EPCs. Moreover, B19V infection per se did not affect STAT5 phosphorylation (Fig. 2-14B). Of 
note, the binding of pSTAT5 to the Ori, which locates in front of the B19V P6 promoter, did not 
obviously transactivate the P6 promoter (Fig. 2-15). Thus, our results provide the first evidence 
that an authentic virus, B19V, depends on direct binding of pSTAT5 to its replication origin 
(Ori) for viral DNA replication.   
Phosphorylated STAT5 interacts with the MCM complex and recruits it to viral replication 
origins during DNA replication initiation.  
            B19V infection induces late S-phase arrest in human EPCs, and S-phase factors are fully 
utilized by the virus to replicate its genome (68). During cellular DNA replication, ORC-CDC6-
CDT1 binding to the replication origin is a priming event that takes place in G1-phase (169). 
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Furthermore, CDT1 recruits the MCM complex and subsequently the whole replisome via 
formation of the MCM-CDC45 complex (169). Notably, no such priming takes place during S-
phase, so that chromosomes are not replicated multiple times (165). However, viruses have 
evolved different mechanisms to initiate viral DNA replication. For examples, SV40 has the 
large T antigen that binds SV40 DNA replication origin and has helicase activity, and also 
recruits the replication machinery by interacting with DNA replication factors, such as 
replication factor A, DNA polymerase α and topoisomerase I (175). Parvoviruses use the large 
non-structural protein NS1, which binds directly to the viral origin and has helicase and nickase 
activities that facilitate viral DNA replication (176). In parvovirus AAV, the MCM complex is 
essential to AAV2 DNA replication in vitro (168), and is probably recruited by interaction with 
Rep78, the large viral non-structural protein (177).  
In the case of B19V, the MCM complex is localized to the viral DNA replication centers 
and is required for viral DNA replication (68). However, we did not observe any interaction 
between the B19V NS1 protein and the MCM complex, suggesting that the complex is recruited 
to the viral DNA replication centers by an alternative mechanism. Here, our results provided 
evidence that STAT5 interacts with the MCM complex in human EPCs, without involvement of 
viral or cellular DNA. These cells express STAT5A more abundantly than STAT5B (Fig. 2-
12A), but both STAT5A and STAT5B proteins interact with the MCM complex (Fig. 2-12C).   
During B19V infection, STAT5 is recruited to the viral DNA replication origin by direct 
interaction with STAT5BEs in the Ori sequences of the viral genome, thereby bringing the 
MCM complex to the viral Ori. Outside of the Ori, there are additional 6 putative STAT5BEs, 
and we tested that two of them in the capsid proteins-coding region also bound pSTAT5 (Fig. 2-
13D). Since there is no putative terminal resolution site (trs) and NS1-binding sites outside of the 
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Ori, we speculate that these STAT5BEs outside of the Ori do not contribute to B19V DNA 
replication. We hypothesize that MCM complex recruited by pSTAT5 at Ori may contribute to 
virus replication through its helicase activity or the recruitment of other DNA replication factors 
to the viral origin (169). Notably, PIF (parvovirus initiation factor), a member of the KDWK 
family of transcription factors, has been shown to bind two adjacent “ACGT” motifs in front of 
the NS1 binding site of left-hand replication origin (OriLTC) of the Protoparvoviurs minute virus 
of mice (MVM) (178,179). PIF stabilizes the binding of NS1 to the Ori, which is critical for the 
activation of NS1 nickase (180). In B19V, at least in an in vitro nicking assay, B19V NS1 is 
sufficient to cleave the Ori (62). However, whether the binding of STAT5 to B19V Ori or the 
recruited MCM complex also involves in NS1 nickase activity of the Ori at trs (Fig 2-2A) 
warrants further investigation.        
Pimozide, an FDA-approved drug, shows promise for the treatment of B19V infection.  
            To date, no specific treatment (either anti-viral or vaccine-based) exists for B19V 
infection. We have now demonstrated that pimozide, an FDA-approved anti-psychotic drug that 
is used in the treatment of a wide range of diseases (181) and could be potentially used to treat 
chronic myeloid leukemia, in which it specifically targets cancer cells, without affecting CD34+ 
hematopoietic stem cells (149). Pimozide specifically inhibits STAT5 phosphorylation without 
affecting JAK2 activation or JAK2-derived signaling pathways; however, the underlying 
mechanism is unknown yet (182). The pSTAT5 is presumably required for recruitment of the 
MCM complex to the viral Ori, and facilitates B19V replication in human EPCs. Pimozide is a 
potent inhibitor of B19V replication, with an IC50 of ~2.7 µM. At 15 μM, pimozide does not 
have a significant effect on proliferation of human EPCs expanded ex vivo, and has only 
moderate effect (~15% reduction) on colony formation of EPCs. As STAT5A phosphorylation 
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plays a key in B19V replication in human EPCs under hypoxic conditions (18), these lines of 
evidence suggest that the inhibition of B19V replication in CD36+ EPCs is not a side-effect of 
the pimozide. Antivirals such as cidofovir and ribavirin are used in the treatment of adenovirus 
infection, and have IC50 values of 15 µM for cidofovir and 25 µM for ribavirin (183). 
Importantly, when we applied both pimozide and STAT5-SH2i (at 15 and 250 µM, respectively), 
a significant synergistic inhibition of B19V infection was observed (Fig. 2-16). Therefore, we 
expect that a clinical trial should be conducted to examine pimozide as a treatment for B19V 
infection of patients with sickle-cell disease and immunocompromised patients and as anti-viral 

















Fig 2-1. Pimozide abolishes B19V replication in primary CD36+ erythroid progenitor cells 
(EPCs). 
            (A) Inhibition of phosphorylation of STAT5 by pimozide. CD36+ EPCs were treated with 
dimethyl sulfoxide (DMSO) vehicle or pimozide at various concentrations. At 48 h post-
treatment, cells were collected, washed and lysed for Western blotting with detection of pSTAT5 
by anti-pSTAT5(Y694) antibody. The blot was reprobed for total STAT5 using a mouse anti-
STAT5 antibody and for β-actin as a loading control. (B-D) Inhibition of B19V DNA replication 
by pimozide. CD36+ EPCs were pre-incubated with DMSO or pimozide at a final concentration 
of 15 µM or 25 µM 6 h prior to B19V infection. At 48 h post-infection, cells were subjected to 
(B) flow cytometry analysis for the B19V-infected cell population with an anti-B19V capsid 
antibody, (C) Hirt DNA extraction, followed by Southern blot analysis with a B19V M20 DNA 
probe, or (D) Western blotting with an anti-pSTAT5(Y694) antibody, and reprobing with an 
anti-β-actin antibody. (E&F) Evaluation of the effect of pimozide on cell proliferation. CD36+ 
EPCs were treated with either DMSO or pimozide (15 µM or 25 µM). After 48 h, treated cells 
were incubated with bromodeoxyuridine (BrdU) for 1 h to analyze cell-cycle progression by a 
BrdU incorporation assay. (E) Results of a representative cell-cycle analysis experiment. (F) 
Relative fold change in the S phase cell population of each group is shown, with means and 
standard deviations of three independent experiments. P values are calculated using one-way and 
Tukey-Kramer post-test, compared with DMSO control. * denotes P<0.05; **** denotes 
















Fig 2-2. STAT5 interacts with B19V replication origins (Ori) in vitro.   
            (A) Diagram of the B19V ssDNA and replicative form (RF) DNA genome. B19V 
genomes of the single-stranded (ss) DNA form and full-length replicative form (RF) are 
depicted, along with the sequence of viral Ori that contains a consensus STAT5-binding element 
(STAT5BE), terminal resolution site (trs), two NS1-binding elements (NSBE1 and NSBE2), and 
two putative cellular factor-binding elements (CFBE) (58,62,77). (B) Probes used in 
electrophoretic mobility shift assay (EMSA). Sequences of two 39-nt probes, wt-Ori-39 and mut-
Ori-39, are shown with the consensus STAT5BE and the mutated STAT5BE (mSTAT5BE) 
highlighted. (C&D) EMSA. (C) 32P-labeled Ori probes wt-Ori-39 (lane 2) and mut-Ori-39 (lane 
3) were incubated with UT7/Epo-S1 nuclear lysate (NL) in the presence of non-specific 
competitor poly dI-dC. Products were subjected to non-denaturing 5% polyacrylamide gel 
electrophoresis (PAGE). Gels were dried and exposed to a phosphor screen. (D) Similarly, 
EMSA was performed with 32P-labeled wt-Ori probes and 5 µg of NL in the presence of 5 µg of 
anti-pSTAT5(Y694) or IgG control antibody. (E) PAGE analysis of purified pSTAT5. 20 μl of 
pSTAT5 was analyzed by SDS-10% PAGE. Gels were either stained with Coomassie brilliant 
blue (left panel/CBB staining), or transferred to a PVDF membrane for Western blotting with an 
anti-pSTAT5(Y694) antibody (right panel/Western blot). (F&G) EMSA with purified pSTAT5. 
(F) 32P-labeled wt-Ori-39 (lane 2) and mut-Ori-39 (lane 3) probes were incubated with purified 
pSTAT5 in the presence of poly dI-dC. Samples were run on 5% non-denaturing PAGE, dried, 
and exposed to a phosphor screen. (G) EMSA with wt-Ori-39 in the absence (lanes 2&3) or 
presence of STAT5-SH2i at 0.3 mM (lane 4), 0.5 mM (lane 5), and 0.8 mM (lane 6). Lane 1, wt-




       




Fig 2-3. STAT5 colocalizes with B19V NS1, capsids, and the replicating B19V genome. 
            (A&B) STAT5 colocalizes with B19V NS1 and capsids. Mock- or B19V-infected CD36+ 
EPCs were co-stained and examined with rabbit anti-STAT5 and rat anti-B19V NS1 antibodies 
(A) or with rabbit anti-STAT5 and mouse anti-B19V capsid antibodies (B). (C-E) Proximity 
ligation assay. Infected cells were co-stained with rabbit anti-STAT5 and mouse anti-B19V 
capsid antibodies (C), or co-stained with rabbit anti-STAT5 and mouse anti-BrdU antibodies 
(D), or co-stained with mouse anti-B19V capsid and rabbit anti-BrdU antibodies (E), followed 
by a proximity ligation assay, which produces amplified signal for labeled molecules in close 
proximity. (F) STAT5 colocalizes with the replicating viral genome. Mock- or B19V-infected 
CD36+ EPCs were BrdU labeled to identify replicating viral ssDNA genomes. The treated cells 
were co-stained with rabbit anti-STAT5 and mouse anti-BrdU antibodies, followed by incubation 
with secondary antibodies. Images were taken with an Eclipse C1 Plus (Nikon) confocal 













             
  





Fig 2-4. Chromatin immunoprecipitation (ChIP) assay.  
            ChIP assay was performed using either infected CD36+ EPCs or transfected UT7/Epo-S1 
cells, as indicated. (A) Crosslinked chromatin was sheared by sonication to sizes of ~500 bp. (B) 
An anti-pSTAT5(Y694) antibody or negative control IgG was used to pull down DNA-protein 
complexes. Recovered DNA from UT7/Epo-S1 cells or CD36+ EPCs was examined for viral 
DNA by PCR with primer sets of F1/R1 and F1/R2, respectively, which span the Ori sequences 
of the B19V genome. pM20 plasmid was used as a template for positive controls of PCR. (C) A 























           
                               
 
 







Fig 2-5. Blockage of interaction between STAT5 and B19V Ori DNA inhibits B19V 
replication. 
            (A) STAT5-SH2 inhibitor (STAT5-SH2i) abolishes the shift of viral Ori in EMSA. 
UT7/Epo-S1 nuclear lysate (NL) was incubated with 32P-labelled wt-Ori-39 probe (lanes 2-5) 
with the addition of DMSO (lane 3) or STAT5-SH2i at 0.4 mM (lane 4) and 0.8 mM (lane 5). 
(B&D) STAT5-SH2i significantly inhibits viral DNA replication. CD36+ EPCs were incubated 
with either DMSO or STAT5-SH2i (250 μM or 500 μM), 6 h prior to infection. At 48 h post-
infection, cells were collected and subjected either to (B) flow cytometry analysis for the B19V-
infected (B19V+) cell population, with an anti-capsid antibody, or to (C) Hirt DNA extraction 
for Southern blot analysis with a B19V M20 DNA probe (upper panel), with mitochondrial DNA 
(Mito DNA) probed as a loading control (lower panel), or to (D) protein extraction for Western 
blotting with anti-pSTAT5 and anti-β-actin. (E&F) Effect of STAT5-SH2i on cell proliferation. 
CD36+ EPCs were treated with either DMSO or STAT5-SH2i (250 µM or 500 µM), and were 
then incubated with BrdU to perform BrdU incorporation assays. (E) Results of a representative 
cell-cycle analysis. (F) Relative fold changes in the S-phase cell population of each group shown 
with means and standard deviations of three independent experiments. P values are calculated 
using one-way ANOVA and Tukey-Kramer post-test (P>0.05), compared with DMSO control. 
















Fig 2-6. Failure of B19V replicative form DNA clones with STAT5-binding element 
mutations in replication in transfected UT7/Epo-S1 cells. 
            (A) Diagram of the B19V full-length M20 RF genome and various half ITR-deleted N8 
RF genomes with mutations at STAT5-binding elements (STAT5BEs). Red squares indicate the 
position of the Ori sequences at both ITRs, and grey squares indicate mutated Ori (mOri). The 
sequence of the mOri is shown with mutated nucleotides in grey in the STAT5BE. (B&C) 
Southern blot analysis. (B) The N8 RF DNA, or derivatives with mutations in the STAT5BE of 
either the left ITR (N8OriL), right ITR (N8OriR), or both (N8mOri), were transfected into UT7/Epo-
S1 cells. (C) M20, and M20mOri, a derivative of the M20 RF DNA with STAT5BEs of both ITRs 
mutated, were transfected into UT7/Epo-S1 cells. At 48 h post-transfection, cells were collected 
for Hirt DNA extraction. And Hirt DNA samples were analyzed by Southern blotting with an 
M20 DNA probe. RF DNA (RF), ssDNA (ss), and Dpn I-digested DNA (shown with a line) are 
indicated. Mitochondrial DNA (Mito DNA) was used as a loading control (lower panels). (D) 
Viral protein expression of B19V DNA mutants. M20 or M20mOri transfected UT7/Epo-S1 cells 
were stained with anti-NS1 or anti-capsid antibodies. Confocal images were taken with an 
















Fig 2-7. pSTAT5, but not NS1 interacts with the MCM complex. 
            (A) Immunoprecipitation (IP) assay. Cell lysates of NS1Flag-expressing UT7/Epo-S1 cells 
were prepared for pull-down assays with either anti-Flag-conjugated beads or control beads. 
Immunoprecipitated proteins were examined for the presence of MCM2 by Western blotting. 
Blots were reprobed with rabbit anti-pSTAT5(Y694), anti-E2F5, and anti-Flag antibodies. 
Detection of E2F5 was used as a positive control for NS1 IP. (B) Co-IP assay. UT7/Epo-S1 cells 
were collected, washed, and lysed with RIPA buffer. After centrifugation, the supernatant was 
incubated with either rabbit anti-pSTAT5(Y694) or control IgG antibody. Immunoprecipitated 
proteins were blotted for the presence of the MCM complex with an anti-MCM5 antibody and 
for pSTAT5 with rabbit anti-pSTAT5(Y694). (C) Reverse Co-IP assay. Reverse Co-IP was 
performed with an anti-MCM5 antibody. Immunoprecipitated proteins were examined for 
pSTAT5, MCM2, and MCM5, respectively. (D) Co-IP of lysates treated with DNase. UT7/Epo-
S1 cell lysates, either treated or untreated with DNase (750 units of Benzonase) were incubated 
with anti-pSTAT5(Y694) or control IgG antibodies for Co-IP assay, and immunoprecipitated 
proteins were examined for MCM2 by Western blot analysis. (E-H) Immunofluorescence 
analysis. (E&F) Mock- or B19V-infected CD36+ EPCs were co-stained with rabbit anti-STAT5 
and mouse anti-MCM2 antibodies, followed by (E) incubation with respective secondary 
antibodies, or by (F) proximal ligation assay, which produces amplified signal for labeled 
molecules in close proximity. (G) CD36+ EPCs were incubated with either DMSO or pimozide 
(at 30 µM) for 2 days. And then the cells were co-stained with rabbit anti-STAT5 and mouse 
anti-MCM2 antibodies for proximity ligation assay. (H) Infected EPCs were stained with an anti-
capsid antibody. Confocal images were taken with an Eclipse C1 Plus (Nikon) microscope at 100 
× magnification.   
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Fig 2-8. The MCM complex is loaded onto the viral Ori. 
            (A) Experimental strategy. The STAT5-MCM complex is depicted interacting with a 
DNA sequence, such as the viral Ori. The time line of B19V infection and treatment with the 
STAT5-SH2 inhibitor (STAT5-SH2i) shows time (h) post-infection or post-treatment. (B) ChIP 
assay. Cells were treated as shown in panel A. An anti-MCM2 antibody was used to pull down 
the STAT5-MCM-DNA complex, and the recovered ChIP DNA was subjected to qPCR with a 
primer set spanning the Ori region. Compared with the absence of the STAT5-SH2i, the relative 
abundance (percentage) of MCM on the viral Ori in the presence of the STAT5-SH2i is shown, 
with mean and standard deviation of three independent experiments. P values are calculated 
using a Student’s t test, ** denotes P<0.01. (C) Three color confocal microscopy. Mock- or 
B19V-infected CD36+ EPCs were co-stained with rabbit anti-STAT5, rat anti-NS1, and mouse 
anti-MCM2 antibodies, followed by staining with secondary antibodies conjugated with 
Dylight405, Texas Red, and FITC, respectively. Images were taken with an Eclipse C1 Plus 



























Fig. 2-9. IC50 determination and colony formation assay.  
            (A) IC50 determination. CD36
+ EPCs incubated with pimozide at different concentrations 
were infected with B19V. After 48 h post-infection, the cells were extracted for Hirt DNA. The 
DNA samples were examined for B19V DNA with Southern blot analysis using a M20 RF DNA 
probe. Viral RF DNA was quantified. RF DNA levels with pimozide relative to levels without 
pimozide are plotted against the concentrations of pimozide for the calculation of the IC50 value 
with GraphPad Prism. (B&C) Colony formation assay. CD36+ EPCs were incubated with 
pimozide at different concentrations for 48 h, and then cultured in methyl cellulose-containing 
medium. After 10 days, numbers of the colonies were counted (B). P values are calculated using 
one-way ANOVA followed by Tukey-Kramer post-test, compared with DMSO group. ** 
P<0.01; * P< 0.05; n.s. (P>0.05) denotes no statistical significance. Images of colonies were 














      
 
 




Fig 2-10. Pimozide abolishes B19V DNA replication in UT7/Epo-S1 cells. 
            (A&B) Inhibition of B19V DNA replication. UT7/Epo-S1 cells were pre-incubated with 
DMSO or pimozide (at a final concentration of 10 µM or 20 µM), 6 h prior to M20 transfection. 
Transfected cells were cultured under hypoxic conditions. (A) At 48 h post-transfection, cells 
were collected for Hirt DNA extraction. The DNA samples were subjected to Southern blotting 
with a B19V M20 probe (upper panel). Mitochondrial (mito) DNA was probed as a loading 
control (lower panel). (B) At 48 h post-transfection, cells were collected for Western blotting 
with anti-pSTAT5(Y694). The blot was reprobed for β-actin. (C&D) Evaluation of the effect of 
pimozide on cell proliferation. CD36+ EPCs were treated with either DMSO or pimozide and 
then incubated with BrdU to perform a BrdU incorporation assay. (C) Results of a representative 
cell-cycle analysis. (D) Relative fold changes of the cell population in S-phase are shown with 
means and standard deviations, which were obtained from three independent experiments. P 
values are calculated using one-way ANOVA followed by Tukey-Kramer post-test, n.s. (P> 












       
 
             
  
 





Fig 2-11. Blockage of STAT5-DNA interaction inhibits B19V replication in UT7/Epo-S1 
cells. 
            (A) Southern blot analysis. UT7/Epo-S1 cells were incubated with either DMSO or 
STAT5-SH2 inhibitor (STAT5-SH2i; 250 μM or 500 μM) at 6 h prior to transfection, and then 
the cells were transfected with M20 DNA and cultured under hypoxic conditions. At 48 h post-
transfection, cells were collected for Hirt DNA extraction. The DNA samples were subjected to 
Southern blotting with an M20 DNA probe. Mitochondrial (Mito) DNA was probed as a loading 
control (lower panel). (B&C) Evaluation of the effect of STAT5 inhibitor on cell proliferation. 
UT7/Epo-S1 cells were treated with either DMSO or STAT5-SH2i (at 250 µM or 500 µM), and 
then incubated with BrdU for BrdU incorporation assays. (B) Results of a representative cell-
cycle analysis. (C) Relative fold changes of the cell population in S-phase are shown, with 
means and standard deviations shown. P values are calculated using one-way ANOVA followed 
by Tukey-Kramer post-test, compared with DMSO group. *** denotes P<0.001 and n.s. 












   
 
 









Fig 2-12. STAT5A is the major STAT5 isoform expressed in erythroid lineage cells.  
            (A&B). Differential expression of STAT5A and STAT5B. (A) Cell lysates of UT7/Epo-
S1 and EPCs were subjected to Western blotting with STAT5A/B pan-specific, STAT5A-
specific, or STAT5B-specifc antibodies. Asterisks indicate dimerized or degraded or non-
specific protein bands. (B) Purified STAT5 of UT7/Epo-S1 cells was subjected to Western 
blotting with a STAT5A/B pan-specific antibody. (C) Both STAT5A and STAT5B interact with 
the MCM2 complex. UT7/Epo-S1 cells were collected and lysed with RIPA buffer. The lysates 
were incubated with an anti-MCM2 or control IgG antibody for co-immunoprecipitation (Co-IP). 
Immunoprecipitated proteins were blotted for the presence of STAT5A, STAT5B, and MCM2 
with anti-STAT5A, anti-STAT5B, and anti-MCM2 antibodies, respectively. The precipitated 



















                         
 
 






Fig 2-13. Analyses of MCM or STAT5 binding to B19V genome by ChIP assay.  
            (A) UT7/Epo-S1 cells were transfected with M20 and allowed to replicate for 48 h under 
hypoxic conditions. Cells were collected for ChIP analysis. Anti-MCM2, anti-MCM3, anti-
MCM5, anti-MCM7, and control IgG antibodies were used to pull down DNA-protein complex. 
Recovered DNA was analyzed by qPCR targeting the viral origin (Ori-qPCR). Error bars 
represent standard deviations taken from at least three experiments. P values were calculated 
using a Student’s t test, compared to the IgG control. ** P<0.01; * P<0.05. (B) A diagram of the 
Ori-qPCR amplicon targeting the viral replication origin (Ori) at the left ITR (L-ITR). The 
starting nucleotide numbers of both forward and reverse (F and R) and the location of the probe 
are indicated. (C) UT7/Epo-S1 cells were treated with either DMSO, STAT5-SH2i inhibitor (at 
500 µM) or pimozide (at 25µM), as indicated in the figure, at 6h prior to transfection. Then, the 
cells were transfected with M20 and cultured under hypoxic conditions for 48 h. Cells were 
collected for ChIP analysis using an anti-STAT5 and Ori-qPCR. Error bars represent standard 
deviation taken from at least three experiments. P values were calculated using one-way 
ANOVA followed by Tukey-Kramer post-test, compared with the M20 group. **** denotes 
P<0.0001. (D) Mock- or M20- transfected UT7/Epo-S1 cells, cultured under hypoxic conditions 
for 48 h, were collected for ChIP assay using an anti-STAT5 antibody, followed by PCR using 
primers: forward (F, nt 3135-3156), 5’-  GGA CTG TAG CAG ATG AAG AGC T-3’, and 
reverse (R, nt 3393-3373), 5’-GTG GCC CCC TCA CTC CAC AT-3’, primes as indicated in the 
diagram. Rabbit IgG was used as a negative control of pull-down, and M20 DNA was used as 














Fig 2-14. Pimozide did not affect hydroxyurea-induced ATR/ATM activation, and B19V 
infection did not alter pSTAT5 expression, in CD36+ EPCs. 
            (A) CD36+ EPCs were treated with pimozide (at 15 µM). At 3 h post-treatment, cells 
were incubated with hydroxyurea at 10 mM for 24 h under hypoxic conditions. Then, the same 
numbers of the cells were collected for Western blot analysis of proteins, as indicated, using anti-
ATM(pST1981), anti-ATR(pT1989), pSTAT5, and β-actin, respectively. (B) Mock and B19V-
infected CD36+ EPCs, cultured under hypoxic conditions, were used for Western blot analysis of 




































Fig. 2-15. pSTAT5 did not transactivate viral P6 promoter.  
            (A) A diagram of lentivirus Lenti-ATF/P6-GFP. The virus was made as we reported 
previously (70). (B) UT7/Epo-S1 (S1) cells or NS1-expressing UT7/Epo-S1 (NS1-S1) cells were 
transduced with Lenti-ATF/P6-GFP at an MOI of 2–4 transduction units/cell and cultured under 
hypoxic conditions. At 24 h post-transduction, cells were incubated either with DMSO or 
pimozide (at a final concentration of 15 µM) for 48 h. Then, the cells were collected and 
subjected to flow cytometry analysis for a mean fluorescence intensity (MFI) value of GFP 
expression. P values are calculated using one-way ANOVA followed by Tukey-Kramer post-
test, compared with DMSO group. **** denotes P<0.0001 and n.s. (P>0.05) for no statistical 






























Fig 2-16. Pimozide and STAT5-SH2i synergistically inhibited B19V infection.  
CD36+ EPCs were pre-incubated with DMSO or pimozide (at 15 µM), STAT5-SH2i (at 
250 µM), or pimozide plus STAT5-SH2i (at 15 and 250 µM, respectively), 6 h prior to B19V 
infection under hypoxic conditions. (A) At 48 h post-infection, cells were subjected to flow 
cytometry analysis using anti-B19V capsid antibody. Error bars represent standard deviation 
taken from at least three experiments. P values are calculated using one- way ANOVA followed 
by Tukey-Kramer post-test, compared with DMSO group. **** denotes P<0.0001. (B) Similarly, 
at 48 h post-treatment, uninfected cells were labeled with BrdU for cell cycle analysis. Numbers 


































Chapter 3:  
RNA Binding Protein RBM38 Regulates Expression of the 11-kDa Protein of Parvovirus 
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Human parvovirus B19 (B19V) expresses a single precursor mRNA (pre-mRNA), which 
undergoes alternative splicing and alternative polyadenylation to generate 12 viral mRNA 
transcripts that encode two structural proteins (VP1 and VP2) and three nonstructural proteins 
(NS1, 7.5-kDa, and 11-kDa). Splicing at the second 5’ donor site (D2) of the B19V pre-mRNA is 
essential for the expression of VP2 and 11-kDa. We have previously identified that a cis-acting 
intronic splicing enhancer 2 (ISE2) that lies immediately after the D2 site facilitates recognition 
of the D2 donor for its efficient splicing. In this study, we report that ISE2 is critical for 
expression of the 11-kDa viral non-structural protein. We found that ISE2 harbors a consensus 
RNA-binding motif protein 38 (RBM38) binding sequence–5’-UGUGUG-3’. RBM38 is 
expressed during the middle stage of erythropoiesis. We first confirmed that the RBM38 binds 
specifically with the ISE2 element in vitro. Knockdown of RBM38 significantly decreases the 
level of the spliced mRNA at D2 that encodes 11-kDa protein and, thereafter, expression of the 
11-kDa protein, but not the D2-spliced mRNA that encodes VP2. Importantly, we found that the 
11-kDa protein enhances viral DNA replication and virion release. Accordingly, knockdown of 
RBM38 decreases virus replication via downregulating 11-kDa expression. Taken together, these 
results suggest that the 11-kDa protein facilitates B19V DNA replication, and that RBM38 is an 









Human parvovirus B19 (B19V) belongs to genus Erythroparvovirus of the Parvoviridae 
family (140). B19V productive infection displays a high tropism for burst forming unit-erythroid 
(BFU-E) and colony forming unit-erythroid (CFU-E) progenitor cells in human bone marrow 
and fetal liver (3-5,115). B19V also infects non-erythroid tissues (19); however, the infection is 
not productive (1). B19V infection causes human diseases, such as erythema infectiosum or fifth 
disease in children, transient aplastic crises in sickle cell disease patients, pure red blood aplasia 
in immunocompromised patients, arthropathy, cardiomyopathy in adults, and non-immune 
hydrops fetalis in pregnant women (1,142,144).  
B19V is a small, non-enveloped virus with a single-stranded (ss) DNA genome of 5.6 kb 
(140). The B19V genome is flanked by two identical inverted terminal repeats (ITRs) at both 
ends (Fig. 3-1A) (141). The left portion of the genome encodes nonstructural proteins NS1 and 
7.5-kDa, whereas the right side encodes structural proteins VP1 and VP2, and an additional 
nonstructural protein 11-kDa (Fig. 3-1B) (43,46,47). B19V genome has a single promoter at map 
unit 6 (P6), which transcribes a single precursor mRNA (pre-mRNA) (1). B19V pre-mRNA has 
two donor sites (D1 and D2) and four acceptor sites (A1-1, A1-2, A2-1, and A2-2), which are 
used for alternative splicing to generate all species (12) of the viral mRNAs (Fig. 3-1B). There 
are two internal (proximal) polyadenylation sites, (pA)p1 and (pA)p2, and one distal (pA)d site 
(1). NS1 and 7.5-kDa mRNAs use the (pA)p1/2 sites, and VP1, VP2, and 11-kDa mRNAs utilize 
the (pA)d site for polyadenylation (Fig. 3-1B) (44). 
In absence of virus genome replication, most of the viral transcripts are polyadenylated at 
(pA)p sites in both B19V-permissive and non-permissive cells, the majority of which encode 
NS1 and 7.5-kDa proteins (48,49). However, virus genome replication overcomes the blockade 
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and enhances the read-through of the (pA)p sites, generating full-length transcripts that encode 
capsid and 11-kDa proteins (49). In the past, our group and others used a B19V replication-
competent model, where a nearly full-length B19V genome was amplified by the SV40 
replication origin in COS-7 cells, to analyze the B19V transcription profile (43,44,49,184,185). 
Using that artificial viral DNA replication system, we demonstrated that efficient splicing of the 
first intron promotes the polyadenylation at (pA)p (53). However, splicing within the second 
intron competes with polyadenylation at (pA)p and stimulates polyadenylation at (pA)d (53). We 
also showed that binding of small nuclear U1 RNA to splice donor site D2 is sufficient to inhibit 
polyadenylation at (pA)p (53). Importantly, we previously found multiple splicing enhancers that 
define the central exon, which spans A1-1/A1-2 to D2 sites, determine its inclusion (52). 
Notably, we identified an intronic splicing enhancer 2 (ISE2) after the D2 site of B19V pre-
mRNA, and demonstrated that ISE2 sequence (Fig. 3-1C) is essential for the recognition of D2 
site for splicing (52). Use of morpholino antisense oligonucleotide to ISE2 region reduced 
splicing at D2 site in B19V infected ex vivo expanded human erythroid progenitor cells (52). 
In this study, we showed that RNA-binding motif protein 38 (RBM38) protein binds to 
B19V ISE2 element, which is essential for efficient splicing of B19V pre-mRNA at D2 site. We 
showed that knockdown of RBM38 reduced the level of viral mRNA transcripts encoding 11-
kDa protein. Importantly, the 11-kDa protein augmented virus DNA replication and, thereafter, 
virion release. Overall, our results revealed that RBM38 regulates B19V DNA replication via 
enhancing B19V pre-mRNA splicing at D2 site which ensures the production of viral mRNA 





Materials and Methods 
Ethics statement. 
Primary human CD133+ hematopoietic stem cells were isolated from bone marrow of 
healthy donors according to a protocol (04-H-0179) approved by the National Heart, Lung, and 
Blood Institute institutional review board. There was no donor information associated with 
samples when we received the cells.    
Primary cells and cell lines. 
Human CD133+ hematopoietic stem cells were expanded ex vivo to CD36+ EPCs in 
Wong medium, as described previously (70,78). Briefly, CD133+ cells were cultured in Wong 
medium under normoxia (5% CO2 and 21% O2) up to day-4 and frozen in liquid nitrogen. In 
each experiment, Day-4 cells were seeded under normoxia for 2-3 days, prior to incubation under 
hypoxia (5% CO2 and 1% O2) for 2 days. 
UT7/Epo-S1, a human megakaryoblastoid cell line (14,77), was cultured in Dulbecco’s 
modified Eagle’s medium with 10% fetal bovine serum and erythropoietin (2 units/ml; Amgen, 
Thousand Oaks, CA). UT7/Epo-S1 cells were cultured at hypoxia (1% O2) for 2-3 days post-
transfection. 
UT7/Epo-S1 cells were transduced with lentiviruses expressing shRBM38-1&3. The cells 
were further selected at increasing concentration of puromycin (1 to 5 μg/ml) and passaged for 
several weeks to generate the RBM38-knocked down UT7/Epo-S1 cell line. 
Virus and infection. 
Plasma sample no. P430 containing B19V (~1 ×1012 viral genome copies (vgc)/ml) were 
obtained from ViraCor Eurofins Laboratories (Lee’s Summit, MO). CD36+ EPCs were infected 
with B19V at a multiplicity of infection (MOI) of 1,000 vgc per cell. The infected cells and the 
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media were collected after 2-3 days post-infection for Southern/Western blot analyses and for the 
quantification of the virion release, respectively. 
Plasmid constructions.  
11-kDa knockout M20 clone (pM2011KO): The three ATG’s in 11-kDa ORF of pM20 
were mutated to ACG’s using overlap PCR approach, as described previously (52,53). 
 pLKO constructs: Lentiviral vector pLKO.1 with mCherry reporter was used to clone 
shRNA sequences between Age I and EcoR I sites. pLKO.1-containing scramble shRNA 
sequence was used as control (70). Following shRNA sequences were obtained from Sigma (St. 
Louis, MO) for knocking down RBM38: shRBM38-1:5’- CCG GCG GCT TCT CTT TAA TCT 
AGG TC TCG AGA CCT AGA TTA AAG AGA AGC CGT TTT TTG-3’; shRBM38-2: 5’-
CCG GGA CGA CGA TAG TGT TTC TGT ACT CGA GTA CAG AAA CAC TAT CGT CGT 
CTT TTT TG-3’; shRBM38-3: 5’-CCG GCA ACG TGA ACC TGG CAT ATC TCT CGA GAG 
ATA TGC CAG GTT CAC GTT GTT TTT TG-3’; shRBM38-4: 5’-CCG GGA AAC CTG 
AAA GCA AGA AGT TCT CGA GAA CTT CTT GCT TTC AGG TTT CTT TTT TG-3’. 
pLenti-11-kDa construct: pLenti vector was used to clone optimized 11-kDa ORF 
between the restriction sites Xba I and Sal I, as described previously (17,70). 
Transfection.   
UT7/Epo-S1 cells were electroporated with 2 μg of B19V DNA fragments, as reported 
earlier (70,78), using solution V from Amaxa Nucleofector (Lonza, Basel, Switzerland). B19V 
infectious clone pM20 and mutant pM2011KO were digested with Sal I to release B19V duplex 





RNase protection assay. 
          Total RNA was extracted from infected or transfected cells, using TRIzol reagent 
(Invitrogen). RNase protection was performed as described previously (52,53). Both D1 and D2 
probes were generated using T7 in-vitro transcription kit MAXIscript® (Ambion), following 
manufacturer’s instructions. The images were captured by Typhoon FLA 9000 imager (GE 
Healthcare) and quantified using Image Quant TL software (GE Healthcare). 
Reverse transcription (RT)-quantitative (q) PCR.  
cDNA was synthesized by using Moloney murine leukemia virus (M-MLV) kit (Life 
Technologies, Carlsbad, CA). A multiplex RT-qPCR system was used to detect B19V-specific 
mRNAs, with β-actin mRNA serving as an internal control (77). For quantification of 11-kDa 
mRNA, forward primer 5’-GAA GCC TTC TAC ACA CCT TTG G-3’, reverse primer, 5’-TGG 
CTG TCC ACA ATT CTT CAG G-3’, and probe 5’-FAM-AGA CCA GTT TCG TGA 
ACT/CTA CAG ATG CA-BHQ-3’ were used (77). For quantification of VP2 mRNA, forward 
primer 5’-GAC CAG TTC AGG AGA ATC AT-3’, reverse primer 5’-TTC TGA GGC GTT 
GTA AGC-3’ and probe 5’-FAM-TCG TGA ACT GTG CAG CTG CCC CTG TG-BHQ1-3’ 
were used (77). All primers and probes were purchased from Integrated DNA Technologies 
(Coralville, IA). The primers and probe for quantification B19V genome were described 
previously (78). 
RNA pulldown assay.  
RNA pulldown assay was performed as described in previously published methods 
(186,187) with some modifications. Briefly, wild-type ISE2 (ISE2-WT) and mutant ISE2 (ISE2-
mut1/2) RNA sequences were chemically synthesized by Integrated DNA Technologies 
(Coralville, IA) with biotinylation at 5’ end. 100 μl of streptavidin slurry (Gold biotechnology 
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Inc., St Louis, MO) was used for each sample and washed three times with Wash buffer [20 mM 
Tris-HCl, pH7.5, 100 mM KCl, 2 mM EDTA, 0.5 mM DTT and 1 × protease inhibitor cocktail 
(Sigma)]. Beads were finally resuspended into 500 μl of Wash buffer and 10 μl of biotinylated 
RNA molecules (ISE2-WT or ISE2-mut1/2, 100 μM) were added to it. The mixtures were 
rotated for 3-4 hr at 4ºC. The beads were spun down and washed again with Wash buffer three 
times and resuspended into 500 μl of RNA binding buffer (20 mM Tris-HCl, pH7.5, 300 mM 
KCl, 0.2 mM EDTA, 0.5 mM DTT, poly I-C 6-10 μg/ml, proteinase inhibitors and RNase 
inhibitor) and 100 μl of nuclear lysate (at a concentration of 3-5 μg/μl) was added to each 
sample. UT7/Epo-S1 nuclear extract was prepared as described previously (70). The mixtures 
were rotated overnight, and then the beads were spun down, washed thrice with Wash buffer. 
The bound proteins were eluted using 60 μl of 2 × Laemmli loading buffer and boiled for 5 mins. 
The samples were run on SDS-PAGE either for Western blotting or Mass spectrometry. 
Electrophoretic mobility shift assay.   
ISE2-WT and ISE-mut1 RNA sequences were synthesized, using a T7 in-vitro 
transcription kit from MAXIscript® (Ambion), and further purified using RNA purification kit 
(Cat. no. R1015, Zymo Research, Irvine, CA), following the manufacturer’s instructions. 
Glutathione S-transferase (GST) and GST-RBM38 proteins were incubated with radiolabeled 
ISE2-WT RNA in presence or absence of cold ISE2-WT and cold ISE2-mut1, as indicated in 
each experiment. Gel shift assay was as performed as reported previously (78,154,188). 
Hirt DNA extraction and Southern blotting.  
Hirt DNA (lower molecule DNA) was extracted from B19V-infected CD36+ EPCs or 
B19V DNA-transfected UT7/Epo-S1 cells, as reported previously (78,189). Hirt DNA extracted 
from transfected cells were Dpn I digested before subjected to Southern blot analysis. B19V 
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M20 DNA was used as a temple for radioactive labeling to generate M20 probe. A mitochondrial 
DNA (Mito-DNA) probe was used as a control for the recovery of the Hirt DNA (190). 
Western blotting. 
Western blotting was performed as reported previously (68,78). Following primary 
antibodies were used: Anti-RBM38 antibody (#sc-365898; Santa Cruz, Dallas, TX), anti-
VP1/VP2 (#MAB8293; Millipore, Billerica, MA), anti-GAPDH (#A01622; GenScript, 
Piscataway, NJ), anti-β-actin (#A5441; Sigma Aldrich, St. Louis, MO), and anti-BrdU (#600-
401-C29; Rockland; Limerick, PA). Anti-NS1 and anti-11-kDa antibodies were produced in 
house, as described previously (67,71). HRP-conjugated anti-mouse IgG and anti-rabbit IgG 
secondary antibodies were purchased from Sigma. 
Virion release and quantification. 
For quantifying virions released from transfected UT7/Epo-S1 cells, M20 and M2011KO 
were electroporated with Sal I-linearized DNA. For quantifying virions released from B19V-
infected CD36+ EPCs, shRNA-transduced CD36+ EPCs were infected with B19V. The cells 
were washed at 3 hr post-infection and cultured under hypoxia. At 3 days post-electroporation, or 
post-infection, 200 μl of supernatant from each cell sample was collected and treated with 
Benzonase® Nuclease (250 U/ml) at 37°C for 2 hr. 10 mM EDTA was added to stop the reaction, 
followed by proteinase K treatment. The nuclease digestion resistant viral genome was extracted 
using DNeasy Blood & Tissue kit (Qiagen, Germantown, MD), following the manufacturer’s 
instructions. Finally, the recovered viral DNA was resuspended into 200 μl of DNase-free H2O, 






Biolayer interferometry was used to calculate the binding affinities of RBM38 with ISE2-
WT and ISE2-mut1 RNA sequences, as reported earlier (157,158). Briefly, biotinylated RNA 
was mounted on Streptavidin biosensors (#18-5019, Forte Bio Inc. Fremont, CA) and then 
equilibrated with RNA binding buffer (20 mM Tris-HCl, pH 7.4, 80 mM NaCl), and then dipped 
into buffer containing RBM38 protein at different concentrations to calculate the binding 
parameters; Kass(association rate constant), Kdiss(dissociation rate constant) and KD was 
calculated using Blitz Pro software. 
Cell cycle analysis.  
BrdU incorporation assay was used to determine the percentage of cell population in S-
phase, followed by flow cytometry, as described previously (70,78). 
Lentivirus production. 
Lentiviruses were produced according to the instructions provided by Addgene 
(http://www.addgene.org/tools/protocols/plko) and purified as described previously (17). Cells 
were transduced with lentiviral vector at a MOI of ~5 transduction units/cell, as described 
previously (17). 
Purification of GST- and 6×histine (His)-tagged RBM38 proteins.   
Bacterially optimized RBM38 ORF was cloned either in pGEX-4T-3 vector with GST 
encoding sequence at 5’ end or in pET30a (+) vector between Nde I and Xho I restriction sites to 
express GST-RBM38 and RBM38-His proteins, respectively. The resulting plasmids were 
transformed into bacterial strain BL21 (DE3) pLysS (Promega, Madison, WI). To induce the 
protein expression, isopropul-D-1-thiogalactopyranoside (IPTG) was added to bacterial culture at 
OD600 = 0.6 at a final concentration of 0.5 mM and the culture was grown for another 2-3 hr at 
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37ºC. GST-RBM38 protein was purified as described previously (191). For the purification of 
RBM38-His, the cells were pelleted down and resuspended into lysis buffer (50 mM Tris, pH 
7.4, 150 mM NaCl, 2 mM dithiothriotol [DTT], 5mM CHAPS, 1% Triton-X100 and 1X- 
protease inhibitor cocktail [Sigma]). The lysate was further sonicated, centrifuged and passed 
through 0.45 μM filter (Thermo). The cleared lysate was mixed with Ni-NTA beads (Qiagen) 
and loaded onto a column. The beads were equilibrated with lysis buffer and then washed with 
lysis buffer, followed by three washes of lysis buffer containing imidazole at 20, 30, and 40 mM. 
During all washing steps, NaCl concentration was raised to 500 mM. The bound protein was 
eluted with elution buffer (50 mM Tris, 500 mM NaCl, 0.05% Triton X-100 and 250 mM 
imidazole). The eluted protein was dialyzed against Tris buffer (20 mM Tris pH 7.4, 100 mM 
NaCl), concentrated, quantified, aliquoted and stored at -80ºC. 
Statistics.  
Statistical analysis was done using Graphpad Prism Version 7.0. Error bars represent 
mean and standard deviation (Mean ± SD) and statistical significance (P values) were 
determined by using student t test. p>0.05, no statistical significance (n.s.); ** denotes p<0.01, 











Intronic splicing enhancer 2 (ISE2) specifically interacts with RBM38 protein.  
Our previously published results demonstrated that intronic splicing enhancer 2 is critical 
for the recognition of D2 site for splicing (52). In an in-silico analysis of the B19V ISE2 RNA 
sequence, we found that ISE2 harbors a 5’-UGUGUG-3’ motif, a consensus sequence that binds 
SUP12, an RBM38 ortholog in C. elegans (192-194). We then asked whether RBM38 interacts 
with ISE2 element of the B19V pre-mRNA. We synthesized WT ISE2 (ISE2-WT) RNA and a 
mutant ISE2 (ISE2-mut1) RNA that is identical to the ISEm3 mutation sequence and has been 
shown to abolish splicing of B19V pre-mRNA at D2 donor site (52) (Fig. 3-2A) and labeled 
them with biotin at their 5’ ends. Upon incubation of the two RNA molecules with UT7/Epo-S1 
nuclear lysates in presence of poly-I: C, we performed a pulldown assay, using streptavidin-
coated beads that bound biotinylated RNA molecules. Upon several washings, the pulled down 
proteins were run on SDS-PAGE for Western blotting. We found that ISE2-WT pulled down 
RBM38, whereas ISE2-mut1 didn’t (Fig. 3-2B, upper panel). Similarly, we mutated only the 
RBM38 binding motif within ISE2 (ISE2-mut2) (Fig. 3-2A) and performed a pull-down assay. 
Like ISE2-mut1, ISE2-mut2 also didn’t pull down RBM38 (Fig. 3-2B, lower panel). Next, we 
purified GST-tagged RBM38 for in vitro binding assays. ISE2-WT RNA was synthesized in 
vitro and radio-labelled with 32P. 32P-labelled hot RNA was incubated with either GST (Fig. 3-
2C, lane 2) or increasing concentrations of the GST-RBM38 (Fig. 3-2C, lane 3-7), and the 
mixtures were run on native gel for gel shift assay. It is evident that RBM38 bound ISE2-WT 
(Fig. 3-2C). In order to confirm whether the interaction is specific, we co-incubated GST-
RBM38 and hot ISE2-WT either with molar excess of cold ISE2-WT or cold ISE2-mut1. Our 
results showed that only ISE2-WT, but not ISE2-mut1, competed with hot-ISE2 WT (Fig. 3-2C, 
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lane 11 vs 12). Further on, to determine the binding affinity of RBM38 with ISE2, we purified 
6×histine(His)-tagged RBM38 (Fig. 3-2D). We synthesized biotinylated ISE2-WT or ISE2-
mut1, and performed in vitro binding assay using biolayer interferometry. The sensograms 
showed the binding kinetics of RBM38 with ISE2-WT at different protein concentrations (Fig. 
3-2E). Upon comparing binding affinities of RBM38 with either WT or mutant ISE2, the results 
showed that ISE2-WT bound RBM38 with a high affinity (91.5 ± 5.15 nM) as compared to 
ISE2-mut1 (597.8 ± 5.23 nM) (Fig. 3-2F). Values for association and dissociation kinetics are 
also provided (Fig. 2G). In conclusion, our results demonstrated that RBM38 binds specifically 
with the ISE2 sequence of B19V pre-mRNA, but not the ISE2-mutated sequence (ISEm3 or 
ISE2-mut1) that did not facilitate B19V pre-mRNA splicing at D2 donor site in cells (52). 
RBM38 is expressed during the middle stage of erythroid progenitor development and 
knockdown of RBM38 significantly decreases splicing of B19V pre-mRNA at the D2 donor. 
It has been reported earlier that RBM38 regulates splicing during erythroid differentiation 
process (195). We then looked into the expression levels of RBM38 during erythroid 
developmental stages. Hematopoietic stem cells were cultured from day-4 until day-14, and the 
cells were collected each day for Western blot analysis of RBM38. As shown in Fig. 3-3A, 
RBM38 expression increased from day-5 through day-12, which is highly coordinated and 
consistent with the time course of B19V infection during erythropoiesis (147).  
Next, using lentiviral system, we knocked down RBM38 in UT7/Epo-S1 cells using 
RBM38 shRNA (shRBM38-1, 2, 3, or 4) expressing lentiviruses, and in CD36+ EPCs using 
shRBM38-1&3 expressing lentiviruses (Fig. 3-3B). RBM38 was successfully knocked down 
(>90% reduction) in both types of cells. Since B19V replication is dependent on the cellular 
DNA replication machinery (68,96), we asked whether knockdown of RBM38 has any impact on 
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cell cycle progression. Using BrdU incorporation assay, we determined the percentage 
population of cells in S-phase. Our results demonstrated that RBM38 knockdown didn’t 
obviously alter the cell proliferation of CD36+ EPCs (Fig. 3-3C&E) and UT7/Epo-S1 cells (Fig. 
3-3D&F). 
 As RBM38 binds ISE2 under in vitro conditions, we next asked whether RBM38 
knockdown affects the splicing efficiency at D2 site. UT7/Epo-S1 and RBM38-knocked down 
UT7/Epo-S1RBM38KD cells were transfected with M20 B19V infectious DNA, and the cells were 
collected after 48 hr post-transfection for total RNA extraction, followed by RNase protection 
assay. Radiolabeled 234-nt long D2 probe was generated and used to detect unspliced and 
spliced RNAs at D2 site (Fig. 3-4A). The result showed that RBM38 knockdown decreased the 
efficiency of B19V pre-mRNA splicing at D2 donor site (Fig. 3-4B, lane 3). Splicing events at 
D2 decreased by 61.1% (Fig. 3-4C), while unspliced RNA remained unaffected (Fig. 3-4D). 
Since D1 donor site isn’t flanked by any RBM38 binding motif, as a control, we performed an 
additional RNase protection assay using D1 probe (Fig. 3-4E) to confirm that RBM38 
knockdown didn’t affect splicing at D1 (Fig. 3-4F). In conclusion, our results demonstrated that 
RBM38 is one of the trans-acting factors required for efficient splicing of B19V pre-mRNA at 
D2 site. 
RBM38 determines 11-kDa expression during B19V replication. 
Splicing of B19V pre-mRNA at D2 site is essential for generation of both viral mRNA 
transcripts encoding VP2 and 11-kDa proteins (Fig. 3-1B). As RBM38 knockdown decreased 
splicing efficiency of B19V pre-mRNA at D2 site, we asked whether such a decrease affects 
VP2 and/or 11-kDa expression at the protein or the mRNA level. To this end, CD36+ EPCs were 
infected with B19V, and UT7/Epo-S1 cells were transfected with M20 infectious clone. The 
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cells were collected at 48 hr post-infection or transfection for Western blot analysis. The result 
showed that 11-kDa, but not VP1 and VP2, was significantly decreased in both B19V-infected 
CD36+ EPCs and M20-transfected UT7/Epo-S1 cells upon RBM38 knockdown (Fig. 3-5A, left 
and right panels, respectively). We then followed up to analyze viral RNAs extracted as total 
RNA samples at 48 hr post-transfection, using reverse-transcription (RT)-qPCR that were 
specifically designed to detect 11-kDa and VP2 mRNAs (Fig. 3-5B), as reported earlier (77). 
The RT-qPCR analyses showed that knockdown of RBM38 in UT7/Epo-S1 cells significantly 
decreased 11-kDa mRNA levels by 6.6-fold (Fig. 3-5C) but the level of VP2 mRNA remained 
unaffected (Fig. 3-5D). Also, there was no obvious change in the levels of NS1-encoding and 
VP2-encoding mRNAs (Fig. 3-5E&F). RT-qPCR analyses of viral RNA samples extracted from 
B19V-infected cells revealed similar results (data not shown).  
RBM38 knockdown decreases B19V DNA replication and the virion release. 
Next, we asked whether RBM38 knockdown affects virus replication. To this end, CD36+ 
EPCs were transduced with scramble shRNA (shScram) and shRBM38-expressing lentiviruses, 
and were infected with B19V at 48 hr post-transduction. The cells were collected at 48 hr post-
infection for determining viral DNA replication and virion release. Surprisingly, our results 
showed that RBM38 knockdown significantly decreased both viral DNA replication (Fig. 3-
6A&B) and virion production (Fig. 3-6C). Similarly, M20-transfected RBM38 knockdown cells 
also showed a decrease in virion production (Fig. 3-8A, compare groups 1&4) and virus DNA 
replication (Fig. 3-8B, compare lanes 1&4), as compared to those from WT M20-transfected 
control UT7/Epo-S1 cells.  
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Thus, our results demonstrated that RBM38 plays an important role in viral DNA 
replication and virion release during B19V infection of CD36+ EPCs as well as in transfection of 
the B19V duplex genome in UT7/Epo-S1 cells. 
11-kDa protein enhances B19V DNA replication and the virion release. 
As knockdown of RBM38 decreases 11-kDa expression, we investigated the role of 11-
kDa in viral DNA replication and virion release. We first constructed an 11-kDa-null M20 
mutant (M2011KO) by silently mutating the three potential AUG sites in the ORF of 11-kDa (Fig. 
3-7A). We confirmed that M2011KO didn’t affect the expression of NS1, VP1, and VP2 (Fig. 3-
7B).  
To determine whether 11-kDa expression has an impact on virus replication, M20 and 
M2011KO clones were transfected into UT7/Epo-S1 cells. At 48 hr post-transfection, cells were 
collected for extraction of Hirt DNA samples which were subsequently subjected to Southern 
blot analysis. As shown in Fig. 3-7C&D, replication of M2011KO is significantly poor than that of 
the WT M20. At 72 hr post-transfection, the media of the transfected cells were collected, 
subjected to DNase I treatment, and further used to quantify the released virions. As shown in 
Fig. 3-7E, M2011KO-transfected cells had a significant decrease in the released virions, compared 
with these WT M20-transfected cells. Collectively, these results strongly supported that 11-kDa 
augments B19V DNA replication and virion release. 
Decreased 11-kDa protein expression in RBM38 knocked down cells contributes to the 
reduced viral DNA replication and virion release.  
 In order to confirm whether RBM38 knockdown decreased viral DNA replication via 
11-kDa inhibition, we generated 11-kDa expressing lentivirus to transduce UT7/Epo-S1 cells. 
UT7/Epo-S1 cells were transfected with M20 and M2011KO, and 11-kDa-expressing UT7/Epo-S1 
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cells were transfected with M2011KO. At 72 hr post-transfection, supernatant and cells were 
collected and examined for virion release and DNA replication, respectively. The results show 
that 11-kDa complementation to M2011KO-transfected cells significantly enhanced virion release 
(Fig. 3-8A, compare groups 2&3) and virus DNA replication (Fig. 3-8B, compare lanes 2&3). 
Similarly, RBM38 knocked down UT7/Epo-S1RBM38KD cells and 11-kDa-expressing UT7/Epo-
S1RBM38KD cells were transfected with M20. At 72 hr post-transfection, supernatants and cells 
were collected and examined for virion release and virus DNA replication, respectively. 
Obviously, we observed that both virion release (Fig. 3-8A, compare groups 4&5) and virus 
DNA replication (Fig. 3-8B, compare lanes 4&5) were significantly higher in 11-kDa-expressing 
UT7/Epo-S1RBM38KD cells than those in non-11-kDa-expressing UT7/Epo-S1RBM38KD cells. 
Overall, the complementation of 11-kDa in UT7/Epo-S1RBM38KD cells recovered ~60% of the 
function of 11-kDa in virion release and viral DNA replication during transfection of the M20 
clone. 
Taken together, these results confirmed that RBM38 plays an important role in B19V 












           Parvoviruses with the limited genome size use alternative splicing and alternate 
polyadenylation to maximize the coding capacity of their genome. B19V pre-mRNA splicing at 
the D2 donor site is critical for the production of VP2- and 11-kDa encoding mRNAs (52). 
However, the remained unspliced mRNAs constitute NS1, 7.5-kDa and VP1 encoding mRNAs. 
B19V tightly regulates pre-mRNA splicing at D2 to maintain the variable expression levels of all 
the five viral proteins. Alternative splicing of pre-mRNA is regulated by both cis-acting elements 
and trans-acting factors that regulate splicing both positively and negatively (196). In the case of 
B19V pre-mRNA splicing at D2, we have earlier identified an ISE2, a cis-acting element that 
facilitates the recognition of D2 donor for splicing (52). In this study, we show that ISE2 is 
essential for the expression of viral 11-kDa protein. A cellular trans-acting factor, RBM38, binds 
ISE2 and regulates splicing at D2 site. Knockdown of RBM38 decreased splicing of B19V pre-
mRNA at D2, which particularly affects the splicing from D2 donor to A2-2 acceptor sites that 
decreases level of mRNAs for encoding 11-kDa protein (Fig. 3-1B, R8&R9). Importantly, we 
show that 11-kDa protein augments viral DNA replication and virion release and that RBM38 
promotes B19V replication via the 11-kDa regulation. 
RBM38 binds to ISE2 and regulates splicing at D2 site and therefore 11-kDa expression.  
            During alternative splicing, the splice donor sites are usually weak, and are regulated by 
the interplay of positive and negative cis-acting elements and trans-acting factors (196). Splicing 
of B19V pre-mRNA at D2 generates either VP2 or 11-kDa encoding mRNAs, while as unspliced 
mRNAs at D2 encode NS1, VP1, and 7.5-kDa proteins (Fig. 3-1, R1, R2, R4&R5). It is obvious 
that D2 splicing needs to be regulated in such a way that expression of all the five proteins is 
maintained at an optimal ratio. We identified at least two cis-elements: exon splicing enhancer 3 
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(ESE3) and ISE2 that regulate D2 splicing (52). While looking for other trans-acting factors, we 
observed that ISE2 carries a 5’-UGUGUG-3’ motif that binds SUP12, an RBM38 ortholog in C. 
elegans (192-194). RBM38 is expressed during middle stage of erythroid differentiation which 
coincides with the time course of B19V infection (Fig. 3-3). Using RNA pulldown assay, gel 
shift assay and biolayer interferometry (Fig. 3-2), our results showed that RBM38 specifically 
binds to ISE2 RNA under in vitro conditions, and the ISE2-mutated sequence (ISEm3 or ISE2-
mut1), which did not facilitate splicing of B19V pre-mRNA at D2 donor site (52), also did not 
specifically bind RBM38. Knockdown of RBM38 in M20-transfected UT7/Epo-S1 cells 
decreased splicing efficiency at D2 site. Surprisingly, the decrease in D2 splicing affected only 
mRNAs encoding 11-kDa, but not VP2-encoding mRNAs (Fig. 3-5), which implies that RBM38 
promotes the splicing of the second intron from D2 to A2-2 sites. It is possible that other ESE3- 
or ISE2-binding factor(s) might be responsible for the splicing of the second intron from D2 to 
A2-1 sites, which remains further investigation in the future. The complex interplay between cis-
acting elements surrounding D2 site and trans-acting factors, at least the RBM38, determine the 
splicing of the second intron and eventually the production of VP2, and 11-kDa proteins. Of 
note, there are at least other five 5’-UGUGUG-3’ motifs in B19V pre-mRNA sequence, among 
which two sites follow the D2’ cryptic donor. We have previously reported that B19V uses a 
cryptic donor D2’, when D2 site is mutated (52). The cryptic donors might also need RBM38, 
since it is followed by similar two 5’-UGUGUG-3’ motifs.  
11-kDa protein enhances B19V DNA replication and the virion release from infected cells.   
            It has been reported that 11-kDa helps in capsid production and viral infectivity (61). We 
asked whether 11-kDa plays any other roles in virus replication. Our results show that 11-kDa 
augments viral DNA replication and virion release (by ~7-10-fold). We have previously reported 
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that erythropoietin (EPO) signaling is essential for B19V replication (17). EPO binds EPO 
receptor, activates JAK2-STAT5 and MEK/ERK pathways (89). We also have demonstrated that 
ERK pathway negatively regulates B19V replication (18), whereas STAT5 phosphorylation is 
critical for viral DNA replication (78). 11-kDa protein has been shown to interact with growth 
factor receptor-bound protein 2 (Grb2) via its proline rich region, a Src homology-3 (SH3)-like 
ligand (90). Grb2 is an adaptor protein that interacts with Ras guanine exchange factor-SOS via 
its SH3 domain, thereby activates MAPK/ERK signal transduction pathway (197). Since 
MEK/ERK pathway impedes B19V replication (18), we speculate that B19V uses 11-kDa 
interaction with Grb2 to disrupt MEK/ERK signaling to promote virus replication. On the other 
hand, during B19V infection, viral DNA replication (136), NS1 (65) and 11-kDa (71) induce 
death of erythroid progenitors. In this study, we examined the role of RBM38 in 11-kDa 
production and its outcomes in context of virus replication. It is possible that the contribution of 
11-kDa to B19V induced cell death can also be modulated via RBM38 regulation. Whether 11-
kDa mediated cell death plays any role in virion release, needs further investigation.   
RBM38 functions as an essential host factor for B19V infection.  
            RBM38 is an RNA recognition motif (RRM)-containing RNA binding protein, a largest 
family of RNA binding proteins (198,199). Diverse roles have been attributed to RBM38 ranging 
from RNA stability (200), mRNA translation (201,202) to regulation of splicing during erythroid 
differentiation (195). In case of B19V, we didn’t observe any change in the expression levels of 
NS1, VP1 and VP2 upon knockdown of RBM38 (Fig. 3-5), therefore, it is less likely that 
RBM38 regulates viral mRNA stability and translation during virus infection. The RBM38 
ortholog SUP12 regulates splicing of various genes in C. elegans (192-194). Here we identified 
RBM38 as one of the trans-acting factors that binds to ISE2, promoting splicing of the second 
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intron from D2 to A2-2 sites that favors the expression of 11-kDa. We show mechanistically how 
B19V uses cellular host factor (RBM38) for its efficient replication. The RBM38 expression 
during the stages when the cells are highly susceptible to B19V infection renders it as one of the 
determinants of B19V tropism. Our hypothetical model for D2 splicing of B19V pre-mRNA is 
that RBM38 binding to ISE2 activates the recognition of the D2 site with the A2-2 acceptor site 
(Fig. 3-9). Since U2 small nuclear ribonucleoprotein (snRNP) recognizes both A2-1 and A2-2 
sites, we speculate that after binding ISE2 element, RBM38 interacts with A2-2 acceptor site via 
an unknown mediator M3 that specifically binds A2-2 acceptor site (Fig. 3-9, M3). We further 
investigated other host factors that bind ISE2 region. Our mass spectrometry analysis showed 
that ISE2 interacts with at least 20 other splicing-related factors (data not shown). These 
candidates need further to be investigated for their role in B19V pre-mRNA splicing. Our overall 
hypothesis is that the two cis-acting elements flanking D2 site, i.e., ESE3 and ISE2, with the help 
of trans-acting factors regulate the expression of at least two viral proteins (VP2 and 11-kDa) 
during B19V replication. Identification of such trans-acting factors will eventually reveal the 
entire scenario of how the D2 donor plays the central role in the processing of B19V pre-mRNA, 










Fig. 3-1. B19V transcription map. 
            (A) B19V genome. Linear single-stranded B19V genome is shown in negative sense with 
unpaired or mismatched bases diagramed as bulges and bubbles. ITR, inverted terminal repeat. 
(B) Transcription profile. B19V duplex genome is shown at the top. P6 represents viral 
promoter, D1 and D2 denote splice donor sites, and A1-1, A1-2, A2-1, and A2-2 denote splice 
acceptor sites. Different open reading frames are shown by different colors (Red, Green, and 
Blue). (pA)p and (pA)d represent polyadenylation sites at proximal and distal ends, respectively. 
At bottom, twelve major RNAs are shown encoding different viral proteins, as indicated. 
Question marks indicate whether the protein is expressed from the species of mRNA is 
unknown. (C) ESE3, D2 and ISE2 elements. Donor 2 site (D2) of the B19V pre-mRNA is 
flanked by exon splicing enhancer 3 (ESE3) on left and intronic splicing enhancer 2 (ISE2) on 





















Fig. 3-2. ISE2 specifically binds RBM38 protein under in vitro conditions. 
(A) ISE2 wild-type (ISE2-WT) and ISE2 mutants (ISE2-mut1/2) RNA sequence. 
These two RNAs shown were used in the following binding experiments. (B) Pulldown assay. 
Biotinylated ISE2-WT and ISE2-mut1/2 were incubated with UT7/Epo-S1 nuclear lysates in 
presence of poly-I:C and then pulled down using streptavidin beads followed by several 
washings. The RNA-bound proteins were eluted and run on SDS-PAGE for Western blotting and 
detected with an anti-RBM38 antibody, as indicated. UT7/Epo-S1 nuclear lysate was run in lane 
1 as control. (C) Gel shift assay. Radioactively labelled ISE2-WT was incubated with either 
purified GST (lanes 2 and 9) or increasing concentrations (5, 10, 50, 100, and 300 nM) of 
purified GST-RBM38 (lanes 3-7, respectively) and run on native gel and then examined for shift 
(left panel). Similarly, GST-RBM38 was incubated with hot ISE2-WT in absence (lane 10) or 
presence of excess amounts of cold ISE2-WT (lane 11) and cold ISE2-mut1 (lane 12) for 
competition assay (right panel). Only RNA was run as controls in lanes 1 and 8) (D) RBM38-
His purification. RBM38-His was purified, as described in Materials and Methods, and 6 μg of 
protein was run on SDS-10%PAGE and then stained with Coomassie brilliant blue dye. (E-G) 
Biolayer Interferometry. (E) BLI sensograms showing overtime association and dissociation of 
RBM38 protein with ISE2-WT at different concentrations. (F) Comparison of binding affinities 
of RBM38 protein (1 μM) with ISE2-WT and ISE2-mut1 RNA molecules. (G) Binding 
parameters to calculate KD values (ratio of dissociation and association rate constants). 






                                                         Fig 3-2  
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Fig. 3-3. RBM38 is expressed during middle phase of erythropoiesis and its knockdown 
doesn’t alter cell cycle progression. 
(A) RBM38 expression during erythroid differentiation process. Hematopoietic stem 
cells (HSC) were cultured from day-4 through day-14. Same numbers of cells were collected on 
each day, lysed and run for Western blot analysis. The blot was detected for RBM38 protein 
using an anti-RBM38 antibody and re-probed for β-actin. (B) RBM38 knockdown. Four 
lentiviruses expressing shRNAs against RBM38 were transduced into UT7/Epo-S1 cells. CD36+ 
EPCs were transduced with shRBM38-1&3. At 3 days post-transduction, the cells were lysed for 
Western blot analysis using an anti-RBM38 antibody. Blots were reprobed for β-actin. (C-F) 
Cell cycle analysis. Lentiviruses expressing shRBM38-1&3 were used to generate RBM38 
knocked down UT7/Epo-S1 cell line (UT7/Epo-S1RBM38KD). CD36+ EPCs were transduced with 
shScram or shRBM38-1&3. BrdU incorporation assay was used to track de novo DNA synthesis 
as described in Materials and Methods. The cells were processed and analyzed for cell cycle 
progression using flow cytometry. Representative diagrams showing cell cycle analysis in 
control and RBM38 knockdown CD36+ EPCs (C) or UT7/Epo-S1 and UT7/Epo-S1RBM38KD cells 
(D). Relative fold change of cell population in S phase were calculated for both CD36+ EPCs (E) 
and UT7/Epo-S1 cells (F). Each experiment was repeated three times for the calculation of 




















Fig. 3-4. RBM38 promotes splicing at D2 donor site. 
(A) Probe designing. Schematic representation of D2 probe showing the spliced and 
unspliced RNA species generated upon RNase protection assay. (B) RNase protection assay. 
Normal UT7/Epo-S1 cells and RBM38 knocked down cells (UT7/Epo-S1RBM38KD) were 
transfected with M20. At 2 days post-transfection, the cells were collected for extraction of total 
RNA. RNA samples were analyzed by RNase protection assay using the D2 probe which was 
designed to detect spliced/unspliced RNAs from the D2 site of B19V pre-mRNA, as indicated. 
RNase protection assay was performed as described in Materials and Methods. (C-D) 
Quantification. The detected spliced (C) and unspliced (D) RNA bands at D2 site were 
quantified in RBM38 knocked down cell samples and compared to normal cell samples 
(arbitrarily set as 100%). The experiment was repeated at least three times to calculate their 
means and standard deviations. (E-F) D1 splicing. Schematic representation of D1 probe 
showing the spliced and unspliced RNA species generated upon RNase protection assay (E). As 
described above, RNA samples were subjected to RNase protection assay using D1 probe to 




























Fig. 3-5. RBM38 regulates 11-kDa expression.  
CD36+ EPCs transduced with a scramble shRNA (shScram) and shRBM38-1&3 
(shRBM38)-expressing lentiviruses were infected with B19V at 2 days post-transduction. 
UT7/Epo-S1 and UT7/Epo-S1RBM38KD cells were transfected with M20. (A) Western blotting.   
The cells were collected at 2 days post-infection or post-transfection, lysed and run for Western 
blotting. Immunoblots were probed for NS1, VP1/2 and 11-kDa proteins, using their respective 
antibodies. Blots were re-probed for GAPDH, as a loading control. (B) Reverse Transcription 
(RT)-qPCR. Specific primers and probes detecting VP2 or 11-kDa mRNA, as diagramed, were 
used for qPCR analysis. (C-F) Detection of 11-kDa, VP2, NS1 and VP1 mRNAs by RT-
qPCR. At 2 days post-transfection, total RNA was extracted from UT7/Epo-S1 and UT7/Epo-
S1RBM38KD cells. The RNA was further used to generate cDNA for the quantification of 11-kDa 
(C), VP2 (D), NS1 (E), and VP1 (F) mRNAs, using the RT-qPCR approach. Quantified viral 
mRNAs were normalized to β-actin mRNA, and mRNAs extracted from M20-transfected control 





















Fig. 3-6. RBM38 knockdown decreases viral DNA replication and virion release.  
CD36+ EPCs were transduced with scramble shRNA (shScram) and shRBM38-1&3 
(shRBM38) lentiviruses. At 2 days post-transduction, the cells were infected with B19V. (A&B) 
Southern blotting. At 2 days post-infection, the cells were collected for Southern blot analysis. 
(A) The blots were probed with M20 probe (upper panel) and mitochondrial DNA probe (Mito-
DNA) (lower panel), respectively. dRF and mRF, double and monomer replicative forms, 
respectively; ssDNA, single-stranded DNA. (B) The replicated (mRF) DNA bands were 
quantified and plotted. (C) Virion release. At 3 days post-infection, the supernatants of infected 
cells were collected for quantification of virion released using qPCR. Results shown were 
average and standard deviations which were obtained from at least three independent 


















                       
 











Fig. 3-7. 11-kDa protein enhances B19V DNA replication and virion release. 
(A) Diagram of M2011KO. 11-kDa knockout M20 clone (M2011KO) is diagramed and 
shown with mutations of three translation initiation codons from ATG to ACG. (B) Western 
blotting. UT7/Epo-S1 cells were transfected with M20 and M2011KO, respectively. At 2 days 
post-transfection, cells were collected, lysed and run for Western blot analysis. The blots were 
detected with anti-VP1/2, NS1, 11-kDa, and GAPDH antibodies. (C&D) Southern blotting. 
UT7/Epo-S1 cells were transfected with M20 and M2011KO. At 2 days post-transfection, Hirt 
DNA samples were extracted from transfected cells and subjected to Southern blotting. (C) The 
blots were probed using M20 probe (upper panel) and mitochondrial DNA (Mito-DNA) probe 
(lower panel), respectively. mRF, monomer replicative form DNA; ssDNA, single-stranded 
DNA. (D) mRF DNA bands were quantified, and the means and standard deviations was 
calculated from three independent experiments. (E) Virion release. At 3 days post-transfection, 
the supernatants from the transfected cells were collected and used for the quantification of 















        
 




Fig. 3-8. RBM38 knockdown deceases viral DNA replication and virion release via reducing 
11-kDa expression.  
UT7/Epo-S1 cells were transfected with M20 or M2011KO, and 11-kDa-expressing 
UT7/Epo-S1 cells were transfected with M2011KO, as indicated. UT7/Epo-S1RBM38KD cells or 11-
kDa-expressing UT7/Epo-S1RBM38KD cells were transfected with M20. (A) Virion release. At 3 
days post-transfection, the supernatant from each transfected sample were collected and used for 
virion quantification by qPCR. (B) Southern blot analysis. At 3 days post-transfection, cells 
were collected for Hirt DNA extraction. Hirt DNA samples were subjected to Southern blotting 
using M20 and Mito-DNA probes, respectively. dRF and mRF, double and monomer replicative 
































Fig. 3-9.  Proposed model for the role of RBM38 in B19V pre-mRNA processing.  
U1 and U2 represent U1- and U2-small nuclear ribonucleoprotein (snRNP) complexes, 
and M represents protein mediators associated with U1- and U2-snRNPs. RBM38 and ISE2- 
binding proteins (ISE2-BPs) interact with ISE2 sequence, whereas ESE3-binding proteins 
(ESE3-BPs) interact with ESE3 region of the B19V pre-mRNA. Both ISE2 and ESE3 and their 
associated trans-acting factors help in the recognition of D2 site, as shown by arrows. RBM38 
interaction with ISE2 promotes splicing from D2 to A2-2 intron. Question marks indicate 
























   





































Parvovirus B19 (B19V) is one of the few parvoviruses that is pathogenic to humans (1). 
Approximately 40-60% of the world’s population is infected with B19V (203); however, B19V 
infection mostly remains asymptomatic or manifests only with mild nonspecific symptoms, e.g. 
flu-like symptoms or arthralgia, with low levels of viremia. The viral load shoots up when the 
infected individual is under immune-suppression or when erythrocytes are at a high rate of 
turnover, such as in sickle cell disease patients. The presence of a high virus titer leads to extensive 
cell death of erythroid progenitor cells which causes anemia (115). In non-erythroid tissues, the 
B19V infection leads to inflammatory diseases like cardiomyopathy, arthopathy, etc. (19).  Upon 
B19V infection, the single-stranded DNA genome is converted to the double-stranded replicative 
form, which forms a functional origin of DNA replication (Ori) of 67-bp at both ends of the 
genome (77). The Ori contains two NS1 binding elements (NSBE1&2), a terminal resolution site 
(trs) where the DNA is nicked (58), and a STAT5 binding element (STAT5BE) (78). NS1 binds 
Ori as a multimer (5-7), opens up the double-stranded replicative form at the Ori, and then nicks 
the ssDNA form Ori at the trs (62). NS1 plays a very critical role in viral DNA replication (61). It 
is believed that B19V replicates its genome following the rolling hairpin model of DNA 
replication, as described for other parvoviruses (79). Due to the limited coding capacity of the 
genome, the virus replication depends on cellular host factors. We have previously reported that 
B19V infection stalls cells in late S-phase, where the S-phase replication factors are fully utilized 
for viral DNA replication (68). B19V infection also induces DNA damage response by activating 
ATR and DNA-PKcs, which are essential for virus replication (67). The virus has a restricted 
tropism to erythroid progenitor cells from the bone marrow and the fetal liver (17), which depend 
on erythropoietin for their survival and development (87). EPO binds the EPO receptor (EPO-R), 
which activates three major pathways, i.e., MEK/ERK, PI3K and JAK2/STAT5 (89). Our previous 
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results showed that EPO signaling is essential for B19V replication (17). On further examination 
of the EPO-signaling cascade, our results demonstrated that the MEK/ERK pathway negatively 
regulates B19V replication, whereas the PI3K pathway did not play any significant role in virus 
infection (18). However, the JAK2-STAT5 pathway is essential for B19V replication (18). We 
also showed that B19V replicates efficiently under hypoxia,  that the STAT5 signaling is 
upregulated and that the MEK/ERK signaling is downregulated during hypoxia, which in turn 
favor efficient B19V replication (18). 
            EPO-activated JAK2 phosphorylates STAT5, which undergoes dimerization and enters 
the nucleus (170). Phosphorylated STAT5 is critical for B19V DNA replication. Our results 
demonstrated that inhibition of STAT5 phosphorylation abolishes viral DNA replication (Fig. 2-
1). STAT5A is predominantly expressed in erythroid lineage cells rather than in STAT5B (Fig. 
2-12). Knockdown of STAT5A inhibits virus replication in B19V infected EPCs (18), and 
overexpression of a constitutively phosphorylated STAT5 mutant (STAT5A1*6) further 
enhances virus replication (18). Phosphorylated STAT5 is actively recruited to the viral DNA 
replication centers (Fig. 2-3). During the late S phase arrest, the virus replicates its genome using 
various S-phase replication factors, such as DNA polymerases, proliferating cell nuclear antigen 
(PCNA), replication factor A-32 (RPA32), and minichromosome maintenance (MCM) complex, 
etc. (68,80). In cellular DNA replication, the ORC-CDC-CDT1 complex binds to the replication 
origin and CDT1 recruits MCM complex to the origin, which then uses helicase activity to 
unwind the DNA or helps in the recruitment of other replication factors via CDC45 (169). 
However, parvovirus DNA replication initiation does not require the ORC-CDC6-CDT1 
complex, but rather depends on the MCM complex (68). NS1 binds B19V Ori (58), but does not 
interact with the MCM complex (Fig. 2-7). Our in-silico analysis revealed that the B19V Ori 
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contains a consensus STAT5-binding element, which binds phosphorylated STAT5 both in vitro 
as well as in vivo (Fig. 2-2, -3, -4). Our results revealed two important interactions: STAT5 with 
viral Ori, and STAT5 with the MCM complex. Of note, the interaction between STAT5 and the 
MCM complex is independent of the virus infection, implying that the interaction might be 
essential for other cellular functions, which warrants further investigation. Upon inhibition of 
STAT5 phosphorylation, the abundance of the MCM complex on viral Ori decreases 
significantly (Fig. 2-8). STAT5, MCM2 and the replicating viral genome colocalize in the nuclei 
of B19V-infected EPCs (Fig. 2-8), suggesting that B19V utilizes the STAT5-Ori interaction to 
recruit the MCM complex to the viral replication origin. In conclusion, our studies propose a 
novel model of initiation of DNA replication in parvoviruses.         
            To expand the coding capacity of the genome, the single precursor mRNA (pre-mRNA) 
transcribed from the B19V P6 promoter is post-transcriptionally processed into twelve different 
mRNA transcripts. The mRNAs encode two structural (VP1 & VP2) and three non-structural 
proteins (NS1, 11-kDa, and 7.5-kDa) (43-45). However, it is unclear how B19V precisely 
regulates pre-mRNA processing to maintain varying levels of mRNAs encoding different 
proteins. We have previously demonstrated that the expression of all mRNAs encoding capsid 
proteins and the 11-kDa protein depends on viral DNA replication (49). In the absence of virus 
DNA replication, all mRNAs polyadenylate at the (pA) p sites, and therefore only express NS1 
and the 7.5-kDa proteins (49). However, replication of the viral genome facilitates read-through 
of the (pA)p sites and overcomes the blockage to produce full-length mRNA transcripts. 
Importantly, splicing at the D2 donor site is crucial for the expression of the three important viral 
proteins (VP1, VP2, and 11-kDa) (52). The D2 site is a weak splice donor site and the cis-acting 
elements flanking the D2 site play a key role in processing different mRNA transcripts (52). The 
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D2 site is flanked by exon splicing enhancer 3 (ESE3) and intronic splicing enhancer 2 (ISE2), 
that regulate the expression of three important viral proteins (VP1, VP2, and 11-kDa) (52). In in-
silico analysis, we identified a motif of 5’-UGUGUG-3’, a potential binding site for RBM38, in 
the ISE2 region of the viral pre-mRNA flanking the D2 site (Fig. 3-2). Our results demonstrate 
that RBM38 specifically binds to ISE2 under in-vitro conditions (Fig. 3-2). Interestingly, 
erythroid progenitor cells express RBM38 during the middle stages of erythropoiesis (Fig. 3-3), 
when cells are also highly susceptible to B19V infection. Upon knockdown of RBM38 in M20-
transfected UT7/Epo-S1 cells, the splicing efficiency at the D2 site decreased significantly (Fig. 
3-4), which, however, only affects the 11-kDa encoding mRNA (Fig. 3-5). Also, RBM38 
knockdown affected only 11-kDa expression in both M20-transfected UT7/Epo-S1 cells and 
B19V-infected CD36+ EPCs (Fig. 3-5).  
Further on, our result revealed that the 11-kDa protein facilitates B19V DNA replication 
(~10 fold) and thereby also affects virion release (Fig. 3-7). The facts that RBM38 knockdown 
affected virus replication (Fig. 3-6) and that the complementation with 11-kDa rescued the 
phenotype (Fig. 3-8) indicate that RBM38 regulates B19V replication by promoting the 
expression of the 11-kDa protein. The underlying mechanism of 11-kDa mediated augmentation 
of virus replication is unclear; however, we speculate that 11-kDa interaction with Grb2 (90) 
may disrupt the MEK/ERK pathway to promote virus replication. We have previously 
demonstrated that the MEK/ERK pathway negatively regulates B19V replication (18). Since 
both ISE2 and ESE3 elements are critical for splicing at the D2 site, we hypothesize that ISE2 
and ESE3 interact with other host factors, and that the interplay of cis-acting elements and trans-
acting factors regulates splicing at D2, thereby determining the expression of VP1, VP2, and 11-
kDa proteins (Fig. 3-9). In conclusion, RBM38 is an essential factor for B19V pre-mRNA 
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processing that ensures the expression of the 11-kDa protein, which in turn facilitates viral DNA 
replication and regulates the virion release. 
            There is neither specific treatment nor a vaccine for B19V infection and B19V-related 
pathologies. Our current studies identified two key host factors which can be targeted to prevent 
B19V infection. Importantly, phosphorylation of STAT5 is a pre-requisite for B19V replication. 
We showed that pimozide, a STAT5-phosphorylation inhibitor, abolishes virus replication in ex-
vivo expanded CD36+ EPCs (Fig. 2-1). Our results show that pimozide inhibits virus replication 
with an IC50 of 2.7 µM (Fig. 2-9). Pimozide doesn’t significantly alter the cell cycle progression 
and colony formation of EPCs up to 15 µM (Fig. 2-1 & Fig. 2-9). Thus, pimozide, an FDA-
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